

NOTICE TO PHYSICIAN

This sample template letter is provided as a courtesy by QOL Medical, LLC. Please edit this letter to fit your unique experience and do not include statements that do not apply to your patient. QOL Medical is not responsible for any edits made to the letter, makes no representations or warranties with respect to the contents of this letter, and disclaims any liability associated with the use of this letter. This letter contains general reimbursement information and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing. (Remove before printing on physician letterhead.)

(Sample) Letter of Medical Necessity

Insurer

(Address)

Re: **(Patient's name)**

Date of Birth:

Policy Number: **(Patient's ID number)**

Dear **(Insurer's contact's name and title)**:

I am writing to request prior authorization to initiate Sucraid® (sacrosidase) Oral Solution for **(Name of patient)**. This letter provides evidence that this enzyme replacement therapy is medically necessary for **(his/her)** care and that it is an accepted treatment for Congenital Sucrase-Isomaltase Deficiency (CSID). CSID is a rare genetic disorder that affects a patient's ability to digest certain sugars due to absent or low activity levels of two digestive enzymes, sucrase and isomaltase. These enzymes are involved in the digestion of sugar and starch. Untreated patients with CSID experience gastrointestinal symptoms such as diarrhea, gas, bloating, abdominal pain, and, in infants and young children, slow growth.^{1,2}

The following sections provide detailed information about the patient's medical history, a description of the treatment, and the reasons for using Sucraid® in this case.

Patient History and Diagnosis

On **(Date)**, I diagnosed **(Patient name)** with CSID. **(Include complete information on diagnosis and methods used in the determination of diagnosis, such as evaluation of the patient's case history, a disaccharidase assay test using a small bowel biopsy taken during an esophagogastroduodenoscopy [EGD] procedure or a sucrose breath test [hydrogen methane or ¹³C].³ Also, list previous therapies that have been tried and failed [e.g., nutritional counseling, dietary adjustments] and what factors led to the discontinuation of these therapies.)**

In my clinical judgment, a sucrase-isomaltase (*SI*) genetic test is unwarranted in this case. So far, 2,146 *SI* genetic variants have been identified, with 880 *SI* variants presumed to be pathogenic.⁴ Of these 880 pathogenic variants, only 37 have currently been identified to be associated with CSID.⁵ There may be other yet-to-be-identified *SI* genetic variants associated with CSID that are not currently part of an *SI* screen for CSID. In addition, genetic testing for *SI* variants pathogenic

NOTICE TO PHYSICIAN

This sample template letter is provided as a courtesy by QOL Medical, LLC. Please edit this letter to fit your unique experience and do not include statements that do not apply to your patient. QOL Medical is not responsible for any edits made to the letter, makes no representations or warranties with respect to the contents of this letter, and disclaims any liability associated with the use of this letter. This letter contains general reimbursement information and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing. (Remove before printing on physician letterhead.)

for CSID is not currently widely available in the clinical setting. Therefore, genetic testing to diagnose CSID is not feasible in my clinical practice. Furthermore, I do not think genetic testing adds additional clinical information that cannot be obtained with other diagnostic procedures.

Treatment Description and Rationale

Sucraid® is approved by the U.S. Food & Drug Administration and is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). Please see attachments.

I have chosen to treat **(Patient's name)** with Sucraid® based on the history previously stated, and because it is the indicated medical treatment for CSID. I believe the patient's prognosis without Sucraid® is ___. However, with Sucraid®, the prognosis is ___. In summary, Sucraid® is medically necessary in this case and should be covered and/or reimbursed. Please feel free to contact me if you require additional information.

Sincerely,
(Physician's name)

1. Treem WR. Congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr.* 1995;21(1):1-14. doi:10.1097/00005176-199507000-00001
2. Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr.* 2012;55(suppl 2):S7-13. doi:10.1097/01.mpg.0000421401.57633.9
3. Robayo-Torres CC, Opekun AR, Quezada-Calvillo R, et al. 13C-breath tests for sucrose digestion in congenital sucrase isomaltase deficient and sacrosidase supplemented patients. *J Pediatr Gastroenterol Nutr.* 2009;48(4):412-8. doi:10.1097/mpg.0b013e318180cd09
4. Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased Prevalence of Rare Sucrase-isomaltase (SI) Pathogenic Variants in Irritable Bowel Syndrome Patients. *Clin Gastroenterol Hepatol.* 2018 October; 16(10): 1673–1676. doi:10.1016/j.cgh.2018.01.047
5. Chumpitazi BP, Lewis J, Cooper D, et al. Hypomorphic SI genetic variants are associated with childhood chronic loose stools. *PLoS One.* 2020;15(5):e0231891. doi:10.1371/journal.pone.0231891

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

- Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
- Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
- Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.

NOTICE TO PHYSICIAN

This sample template letter is provided as a courtesy by QOL Medical, LLC. Please edit this letter to fit your unique experience and do not include statements that do not apply to your patient. QOL Medical is not responsible for any edits made to the letter, makes no representations or warranties with respect to the contents of this letter, and disclaims any liability associated with the use of this letter. This letter contains general reimbursement information and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing. (Remove before printing on physician letterhead.)

- Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
- Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
- The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
- **DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®.** Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
- Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.



QL60103

Prescribing Information

Sucraid® (sacrosidase) Oral Solution:

DESCRIPTION

Sacrosidase is an enzyme with the chemical name of β -D-fructofuranoside fructohydrolase. The enzyme is derived from baker's yeast (*Saccharomyces cerevisiae*). It has been reported that the primary amino acid structure of this protein consists of 513 amino acids with an apparent molecular weight of 100,000 Da for the glycosylated monomer (range 66,000- 116,000 Da). Reports also suggest that the protein exists in solution as a monomer, dimer, tetramer, and octomer ranging from 100,000 Da to 800,000 Da. It has an isoelectric point (pI) of 4.5.

Sucraid® (sacrosidase) Oral Solution is an oral enzyme replacement therapy.

Sucraid is a pale yellow to colorless, clear solution with a pleasant, sweet taste. Each milliliter (mL) of Sucraid contains 8,500 International Units (I.U.) of the enzyme sacrosidase, the active ingredient.

Sucraid may contain small amounts of papain (see WARNINGS). Papain is a protein-cleaving enzyme that is introduced in the manufacturing process to digest the cell wall of the yeast and may not be completely removed during subsequent process steps. Sucraid contains sacrosidase in a vehicle comprised of glycerin, water, citric acid, and sodium hydroxide to maintain the pH at 4.0 to 4.7. Glycerol (glycerin) in the amount consumed in the recommended doses of Sucraid has no expected toxicity.

This enzyme preparation is fully soluble with water, milk, and infant formula. DO NOT HEAT SOLUTIONS CONTAINING SUCRAID. Do not put Sucraid in warm or hot liquids (see DOSAGE AND ADMINISTRATION, Administration Instructions).

CLINICAL PHARMACOLOGY

Congenital sucrase-isomaltase deficiency (CSID) is a chronic, autosomal recessive, inherited, phenotypically heterogeneous disease with very variable enzyme activity. CSID is usually characterized by a complete or almost complete lack of endogenous sucrase activity, a very marked reduction in isomaltase activity, and a moderate decrease in maltase activity.

Sucrase is naturally produced in the brush border of the small intestine, primarily the distal duodenum and jejunum. Sucrase hydrolyzes the disaccharide sucrose into its component monosaccharides, glucose and fructose. Isomaltase breaks down disaccharides from starch into simple sugars. Sucraid does not contain isomaltase.

Information for Patients

See Patient Package Insert and the Instructions for Use.

Drug Interactions

Fruit Juice

The acidity in fruit juice may reduce the enzyme activity in Sucraid. Administration of Sucraid with liquids other than water, milk, or infant formula has not been studied and is not recommended (see DOSAGE AND ADMINISTRATION, Administration Instructions).

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals with Sucraid have not been performed to evaluate the carcinogenic potential. Studies to evaluate the effect of Sucraid on fertility or its mutagenic potential have not been performed.

Pregnancy

Teratogenic Effects

Animal reproduction studies have not been conducted with Sucraid. Sucraid is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity. Sucraid should be given to a pregnant woman only if clearly needed.

Nursing Mothers

The Sucraid enzyme is broken down in the stomach and intestines, and the component amino acids and peptides are then absorbed as nutrients.

Pediatric Use

The safety and effectiveness of Sucraid for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), have been established in pediatric patients aged 5 months and older. Use of Sucraid for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients (see CLINICAL STUDIES and ADVERSE REACTIONS).

Geriatric Use

Clinical trials of Sucraid did not include patients 65 years of age and older to determine if they respond differently from younger adult patients.

ADVERSE REACTIONS

The following adverse reactions associated with the use of sacrosidase were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In clinical studies of up to 54 months duration, a total of 52 patients were treated with Sucraid. The reported adverse reactions (number of patients) were as follows: abdominal pain (4), vomiting (3), nausea (2), diarrhea (2), constipation (2), insomnia (1), headache (1), nervousness (1), and dehydration (1).

Hypersensitivity reactions (wheezing, rash, and pruritis) have been reported (see WARNINGS).

The effects of Sucraid have not been evaluated in patients with secondary (acquired) sucrase deficiency.

INDICATIONS AND USAGE

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

CONTRAINDICATIONS

Sucraid is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain (see WARNINGS).

WARNINGS

Severe Hypersensitivity Reactions

Severe hypersensitivity reactions, including wheezing, rash, and pruritis, have been reported with administration of Sucraid. Sucraid contains papain, which is associated with hypersensitivity reactions (see DESCRIPTION).

A pediatric patient in the clinical trials experienced a hypersensitivity reaction of severe wheezing that required hospitalization. Postmarketing cases of cutaneous hypersensitivity reactions have also been reported.

Instruct patients or caregivers to stop Sucraid and seek medical attention if symptoms suggestive of a hypersensitivity reaction occur. Sucraid is contraindicated in patients who have had a known hypersensitivity reaction (see CONTRAINDICATIONS).

PRECAUTIONS

Increased Blood Glucose Concentrations in Patients with Diabetes Mellitus

Sucraid enables the products of sucrose hydrolysis, glucose and fructose, to be absorbed and may increase blood glucose concentrations. Monitor blood glucose concentrations and adjust the diet accordingly for patients with diabetes mellitus.

Dietary Starch Restriction

Sucraid does not replace isomaltase. Therefore, patients may still experience symptoms of CSID while taking Sucraid. Consider dietary starch restriction in addition to Sucraid, especially in patients in whom symptoms are not adequately controlled by Sucraid.

Information for Patients

See Patient Package Insert and the Instructions for Use.

Drug Interactions

Fruit Juice

The acidity in fruit juice may reduce the enzyme activity in Sucraid. Administration of Sucraid with liquids other than water, milk, or infant formula has not been studied and is not recommended (see DOSAGE AND ADMINISTRATION, Administration Instructions).

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals with Sucraid have not been performed to evaluate the carcinogenic potential. Studies to evaluate the effect of Sucraid on fertility or its mutagenic potential have not been performed.

Pregnancy

Teratogenic Effects

Animal reproduction studies have not been conducted with Sucraid. Sucraid is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity. Sucraid should be given to a pregnant woman only if clearly needed.

Nursing Mothers

The Sucraid enzyme is broken down in the stomach and intestines, and the component amino acids and peptides are then absorbed as nutrients.

Pediatric Use

The safety and effectiveness of Sucraid for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), have been established in pediatric patients aged 5 months and older. Use of Sucraid for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients (see CLINICAL STUDIES and ADVERSE REACTIONS).

Geriatric Use

Clinical trials of Sucraid did not include patients 65 years of age and older to determine if they respond differently from younger adult patients.

ADVERSE REACTIONS

The following adverse reactions associated with the use of sacrosidase were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In clinical studies of up to 54 months duration, a total of 52 patients were treated with Sucraid. The reported adverse reactions (number of patients) were as follows: abdominal pain (4), vomiting (3), nausea (2), diarrhea (2), constipation (2), insomnia (1), headache (1), nervousness (1), and dehydration (1).

Hypersensitivity reactions (wheezing, rash, and pruritis) have been reported (see WARNINGS).

DOSAGE AND ADMINISTRATION

Important Administration Information

- Administer Sucraid with each meal or snack.
- Mix Sucraid with cold or room temperature water, milk or infant formula prior to administration. Administration of Sucraid in liquids other than water, milk, or infant formula has not been studied and is not recommended. Do not mix or consume Sucraid with fruit juice.
- Do not warm or heat the water, milk, or infant formula before or after addition of Sucraid.
- Administer half of the dose at the beginning of the meal or snack and the other half of the dose during the meal or snack.

Recommended Dosage

The recommended dosage is:

- Patients weighing 15 kg and less:** 8,500 International Units (1 mL) administered orally with each meal or snack.
- Patients weighing more than 15 kg:** 17,000 International Units (2 mL) administered orally with each meal or snack.

Preparation and Administration Instructions for Patients Weighing 15 kg or Less

Multiple-Dose Bottle:

- Using the measuring scoop provided, add 1 scoop of Sucraid (1 mL) to 60 mL of cold or room temperature water, milk, or infant formula.
- Stir to mix well.
- Administer half of the mixed Sucraid solution (30 mL) at the beginning of the meal or snack and the other half of the mixed solution (30 mL) during the meal or snack.
- Do not save any of the mixed Sucraid solution for later use.
- Rinse the measuring scoop with water.

Single-Use Container:

- Empty the entire contents of the single-use container (2 mL) in 120 mL of cold or room temperature water, milk, or infant formula.
- Stir to mix well.
- Divide the mixed Sucraid solution into two separate 60 mL portions. The first portion (60 mL) is for immediate use.
 - Administer half of the first portion (30 mL) of the mixed Sucraid solution at the beginning of the meal or snack and the other half of the first portion (30 mL) of the mixed Sucraid solution during the meal or snack.
- Store the second portion of the mixed Sucraid solution (60 mL) at 2°C to 8°C (36°F to 46°F) for up to 24 hours for administration with the next meal or snack.
- Discard the mixed Sucraid solution if not used within 24 hours.

Preparation and Administration Instructions for Patients Weighing More than 15 kg

Multiple-Dose Bottle:

- Using the measuring scoop provided, add 2 scoops of Sucraid (2 mL) to 120 mL of cold or room temperature water, milk, or infant formula.
- Stir to mix well.
- Administer half of the mixed Sucraid solution (60 mL) at the beginning of the meal or snack and the other half of the mixed Sucraid solution (60 mL) during the meal or snack.
- Do not save any of the mixed Sucraid solution for later use.
- Rinse the measuring scoop with water.

Single-Use Container:

- Empty the entire contents of the single-use container (2 mL) in 120 mL of cold or room temperature water, milk, or infant formula.
- Stir to mix well.
- Administer half of the mixed Sucraid solution (60 mL) at the beginning of the meal or snack and the other half of the mixed solution during the meal or snack (60 mL).
- Do not save any of the mixed Sucraid solution for later use.

HOW SUPPLIED

118 mL Multiple-Dose Bottle

Sucraid (sacrosidase) Oral Solution is available in 118 mL (4 fluid ounces) multiple-dose translucent plastic bottles, packaged two bottles per carton. Each mL of solution contains 8,500 International Units of sacrosidase. A 1 mL measuring scoop is provided with each bottle. A full measuring scoop is 1 mL.

NDC# 67871-111-04 (2 x 118 mL multiple-dose bottles)

Store under refrigeration at 2°C to 8°C (36°F to 46°F). Discard four weeks after first opening due to the potential for bacterial growth. Protect from heat and light.

2 mL Single-Use Container

Sucraid (sacrosidase) Oral Solution is available in 2 mL, single-use containers that are packaged into a foil pouch. Each 2 mL single-use container contains 17,000 International Units of sacrosidase. Each foil pouch holds a card of 5 containers. Five pouches are then packaged in a box (25 containers). Six boxes are further packaged in a carton (150 containers).

NDC# 67871-111-07 (150 x 2 mL single-use containers)

Store under refrigeration, 2°C to 8°C (36°F to 46°F). Protect from light. Single-use container can be removed from refrigeration and stored at 15°C to 25°C (59°F to 77°F) for up to 3 days (72 hours).

Manufactured by:
QOL Medical, LLC Vero Beach, FL 32963
U.S. License No. 2195

www.sucraid.com
For questions call 1-866-469-3773
Rev <08/24>

The most common side effects of SUCRAID include:

- stomach (abdominal) pain
- vomiting
- nausea
- diarrhea
- constipation
- problems sleeping
- headache
- nervousness
- dehydration

These are not all of the possible side effects of SUCRAID. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store SUCRAID?

- SUCRAID 118 mL multiple-dose bottle**
 - Store in the refrigerator between 36°F to 46°F (2°C to 8°C).
 - Throw away after 4 weeks of first opening the multiple-dose bottle.
 - Protect from heat and light.

SUCRAID 2-mL single-use container

- Store in the refrigerator between 36°F to 46°F (2°C to 8°C)
- After removing from the refrigerator, the 2-mL single-use container can be stored between 59°F to 77°F (15°C to 25°C) for up to 3 days (72 hours).
- Protect from heat and light.

Keep SUCRAID and all medicines out of the reach of children.

General information about the safe and effective use of SUCRAID.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SUCRAID for a condition for which it was not prescribed. Do not give SUCRAID to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SUCRAID that is written for health professionals.

What are the ingredients in SUCRAID?

Active ingredient: sacrosidase

Inactive ingredients: Citric acid, glycerol, sodium hydroxide, and water.

Manufactured by:

QOL Medical, LLC Vero Beach, FL 32963
U.S. License No. 2195

For more information, go to www.Sucraid.com or call 1-866-469-3773.

This Patient Package Insert has been approved by the U.S. Food and Drug Administration

Revised: August 2024

Instructions for Use

SUCRAID®(Su-kreid) (sacrosidase) oral solution:
118 mL Multiple-Dose Bottle

Read this Instructions for Use before you start taking or giving SUCRAID to a child, and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your or your child's medical condition or treatment.



Important information you need to know before taking or giving SUCRAID:

- Your healthcare provider will decide the right dose of SUCRAID for you or your child. **Do not** change the dose of SUCRAID without talking to your healthcare provider.
- The dose of SUCRAID depends on body weight. Your healthcare provider will tell you how much SUCRAID you should take or give your child.
 - The dose for a child 33 pounds (15 kg) or less is 1 mL or 28 drops of SUCRAID in 2 ounces of water, milk, or infant formula.
 - The dose for a child or adult more than 33 pounds (15 kg) is 2 mL or 56 drops of SUCRAID in 4 ounces of water, milk, or infant formula.
- SUCRAID can only be dissolved with cold or room temperature water, milk, or infant formula. **Do not** put SUCRAID in warm or hot liquids. **Do not** dissolve SUCRAID with fruit juice. **Do not** take or give SUCRAID with fruit juice.
- Do not** warm or heat the mixed solution before taking or giving SUCRAID.
- Measure your dose or your child's dose of SUCRAID using the measuring scoop that comes with the SUCRAID bottle. **Do not** use a kitchen teaspoon or other measuring device.
- SUCRAID should be taken or given with each meal or snack. Half of the SUCRAID dose should be taken or given at the beginning of each meal or snack. Take or give the remaining SUCRAID dose during the meal or snack.
- Do not** use the SUCRAID multiple-dose bottle if the seal has been damaged. Contact your pharmacist or healthcare provider if you cannot use the SUCRAID multiple-dose bottle.

Supplies needed to take or give SUCRAID:

- SUCRAID 118 mL multiple-dose bottle
- 1 measuring scoop (included in SUCRAID carton)
- 2 to 4 ounces of cold or room temperature water, milk, or infant formula (not included)
- Meal or snack (not included)

How to take or give SUCRAID:

Step 1: Check the expiration date on the SUCRAID bottle. **Do not** use SUCRAID after the expiration date on the bottle has passed.

Step 2: Write down the date the bottle is first opened in the space provided on the bottle label.

Step 3: Each bottle of SUCRAID has a plastic screw cap that covers a dropper dispensing tip. Remove the plastic screw cap by twisting it to the left.

Step 4: Use the measuring scoop that comes in your SUCRAID carton to measure your or your child's prescribed dose. See **Figure 1**. Reseal the bottle after each use by replacing and twisting the plastic screw cap to the right until tight.



Figure 1

Step 5: Mix your or your child's prescribed dose in 2 ounces or 4 ounces of cold or room temperature water, milk, or infant formula as instructed by your healthcare provider. See **Figure 2**.



Figure 2

Step 6: Take or give half of the mixed solution at the beginning of each meal or snack. Take or give the remaining mixed solution during the meal or snack.

Step 7: Rinse the measuring scoop with water after each use.

Throwing away (disposal of) SUCRAID:

• Throw away (discard) the SUCRAID multiple-dose bottle and any remaining medicine in your household trash 4 weeks after first opening.

How should I store SUCRAID?

• Store the SUCRAID multiple-dose bottle in the refrigerator between 36°F to 46°F (2°C to 8°C).

• Protect SUCRAID from heat and light.

Keep SUCRAID and all medicines out of the reach of children.

Manufactured by:
QOL Medical, LLC Vero Beach, FL 32963
U.S. License No. 2195


For more information, go to www.sucraid.com or call 1-866-469-3773.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Issued: May 2022

Instructions for Use

Sucraid® (Su-kreid) (sacrosidase) Oral Solution:
2-mL Single-Use Container

Read this Instructions for Use before you start taking or giving Sucraid to a child, and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your or your child's medical condition or treatment.



Important information you need to know before taking or giving Sucraid:

- The 2-mL single-use container is for children and adults.
- Sucraid is supplied in 2-mL single-use containers in a foil pouch. Each foil pouch holds 5 single-use containers. **Each container is one 2 mL Sucraid dose.**
- Your healthcare provider will decide the right dose of Sucraid for you or your child. **Do not** change the dose of Sucraid without talking to your healthcare provider.
- Sucraid can only be dissolved with cold or room temperature water, milk, or infant formula. **Do not** put Sucraid in warm or hot liquids. **Do not** dissolve Sucraid with fruit juice. **Do not** give or take Sucraid with fruit juice.

• **Do not** warm or heat the mixed solution before taking or giving Sucraid.

• Sucraid should be taken or given with each meal or snack. Half of the Sucraid dose should be taken at the beginning of each meal or snack. Take or give the remaining Sucraid dose during the meal or snack.

• **Do not** use the Sucraid single-use container if the seal has been damaged. Contact your pharmacist or healthcare provider if you cannot use the Sucraid single-use container.

Supplies needed to take or give Sucraid:

- 1 Sucraid 2-mL container
- 4 ounces of cold or room temperature water, milk, or infant formula (not included)
- Meal or snack (not included)
- Spoon to mix (not included)

Step 4: Mix your or your child's prescribed dose in 4 ounces of cold or room temperature water, milk, or infant formula. See **Figure 3**.




Figure 3

Step 5: For patients weighing more than 33 pounds (15 kilograms):

- The entire 4 ounces of mixed solution will be taken or given during each meal or snack. Take or give half of the mixed solution (2 ounces) at the beginning of the meal or snack and take or give the other half of the mixed solution (2 ounces) during the meal or snack.

For patients weighing 33 pounds (15 kilograms) or less:

- Divide the 4-ounce mixed solution into two separate 2-ounce portions.
- Take or give half of the first portion (1 ounce) at the beginning of the meal or snack and take or give the other half of the first portion (1 ounce) during the meal or snack.
- Store the second portion (2 ounces) in the refrigerator at 36°F to 46°F (2°C to 8°C) for the next meal or snack. Take or give half of the second portion (1 ounce) at the beginning of the next meal or snack and take or give the other half of the second portion (1 ounce) during the meal or snack.
- Throw away the second portion (2 ounces) if you do not use it within 24 hours.

Throwing away (disposal of) Sucraid:

• Throw away expired or empty Sucraid containers in your household trash.

How should I store Sucraid?

- Store the Sucraid single-use container in the refrigerator between 36°F to 46°F (2°C to 8°C).
- The Sucraid single-use container may be stored between 59°F to 77°F (15°C to 25°C) for up to 3 days.
- Protect Sucraid from heat and light.

Keep Sucraid and all medicines out of the reach of children.

Manufactured by:
QOL Medical, LLC Vero Beach, FL 32963
U.S. License No. 2195

For more information, go to www.Sucraid.com or call 1-866-469-3773.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: July 2024




Figure 2

Invited Review

Congenital Sucrase-Isomaltase Deficiency

William R. Treem

Division of Pediatric Gastroenterology and Nutrition, Hartford Hospital, and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut, U.S.A.

Sucrase-isomaltase deficiency has received much less attention than lactase deficiency. Although much of the world's population is predisposed to become lactose-intolerant at an early age, the occurrence of sucrase-isomaltase deficiency, either as a result of an inherited condition or secondary to diffuse mucosal injury, is relatively rare. Recently, however, sucrase-isomaltase deficiency has been the focus of increased research activity; important new work has included the elucidation of molecular defects associated with the inherited form of sucrose malabsorption and the recent cloning of the human sucrase-isomaltase gene.

This paper will focus on congenital sucrase-isomaltase deficiency (CSID), including its epidemiology, clinical presentation, and natural history. Normal enzyme structure, synthesis, and processing will be reviewed in order to facilitate understanding of the molecular pathogenesis of CSID. Finally, newer aspects of treatment, including the demonstration of effective enzyme-replacement therapy, will be emphasized. The reader is referred to several excellent reviews for further details (1-3).

SUCRASE-ISOMALTASE: STRUCTURE, BIOSYNTHESIS, AND CONTROL OF ACTIVITY

Role in Digestion (Table 1)

Sucrase-isomaltase (SI) is one of four brush-border disaccharidases. Three of these, including SI, maltase-glucoamylase, and trehalase, are α -glucosidases involved in the digestion of sucrose and starch. After hydrolysis of starch by salivary and pancreatic α -amylases, the resulting products are α

1-4 linked maltose, maltotriose, and malto-oligosaccharides, α 1-6 linked branched dextrans (α -limit dextrans), and glucose. Sucrase hydrolyzes the α 1-4 linked glucose linkages of maltose and maltotriose and the glucose-fructose linkage of sucrose. Isomaltase is an α -glucosidase and cleaves the α 1-6 glucopyranosyl bonds of branched oligosaccharides (α -limit dextrans), the 1-6 linkages of isomaltase, as well as the 1-4 linkages of maltose. The SI complex also hydrolyzes α -glucosides with up to six glucose residues (4). The maltase-glucoamylase complex overlaps with SI activity by hydrolyzing α 1-4 glucose linkages of maltose, maltotriose, starch, glycogen, and other oligosaccharides from their nonreducing ends with maximal affinity for medium-sized polysaccharide chains with 6-10 glucose residues (5). Approximately 80% of the maltase activity is accounted for by SI and only 20% by the maltase-glucoamylase complex. The fourth brush-border disaccharide, lactase-phlorizin hydrolase, is a β -galactosidase that hydrolyzes the β 1-4 linkage of disaccharide but not of cellulose. SI activity is distributed along the whole length of the small intestine. The highest activity occurs in the jejunum, with 20-30% less activity proximal to the ligament of Treitz and distally in the ileum (6).

Structure

SI is a heterodimer complex composed of two similar but not identical subunits. Each subunit consists of a single glycosylated polypeptide chain with an apparent molecular weight in the 120-160 kDa range. Carbohydrate moieties account for ~15% of the molecular mass (7). Recent cloning of the SI cDNA has shown that the SI complex is synthesized as a single precursor of ~260 kDa starting from the N-terminus of isomaltase with ~1827 amino acid residues (3,8).

Address correspondence and reprint requests to William R. Treem at the Division of Pediatric Gastroenterology, Hartford Hospital, 80 Seymour St., P.O. Box 5037, Hartford, CT 06102-5037, U.S.A.

TABLE 1. Role of brush-border enzymes in digestion of disaccharides and starch

Enzyme	Bond cleaved	Substrate	Products
Lactase	β -(1-4) galactosidase (β -glucosidase)	Lactose	Glucose, galactose
Sucrase	α -(1-4) glucosidase	Sucrose, maltose, maltotriose, α -limit dextrans with terminal α 1-4 links	Glucose, fructose malto-oligosaccharide with α 1-6 linkage
Glucoamylase	α -(1-4) glucosidase	Maltose, maltotriose malto-oligosaccharide (glucose polymers with maximal affinity for chains of 6-10 residues)	Glucose, malto-oligosaccharide with terminal α 1-6 linkage
Isomaltase (α -dextrinase)	α -(1-6) glucosidase	Maltose, isomaltose, α -limit dextrans (malto-oligosaccharide with terminal α 1-6 links)	Glucose, malto-oligosaccharides
Trehalase	α - and β -glucosidase (tested on renal trehalase)	Trehalose (found principally in mushrooms)	Glucose

The isomaltase subunit alone interacts with the enterocyte membrane directly via a highly hydrophobic segment at its N-terminal region (Fig. 1). This segment is 20 amino acid residues long and spans the lipid membrane bilayer only once. This domain functions both as a permanent membrane anchor and as a signal peptide that directs targeting to the endoplasmic reticulum (9). It is followed by a 22-residue serine/threonine-rich glycosylated stretch, which presumably forms the stalk on which the globular, catalytic domains are directed into the intestinal lumen (8). The active sites of both enzymes protrude out into the lumen. The sucrase subunit is more peripheral and does not interact with the hydrophobic core of the membrane at all.

After synthesis, glycosylation, and transport to the brush border, prosucrase-isomaltase is rapidly processed by pancreatic proteases, predominantly elastase in the rat and trypsin in humans (10). These proteases cleave the molecule, yielding isomaltase (~125 kDa) and sucrase (~140 kDa). The two subunits remain associated by noncovalent strong ionic interactions. Recent work with rat intestinal membrane vesicles suggests that the postinsertional processing of the prosucrase-isomaltase as well as the structural and functional relationships of the final subunits are much more complex than has been generally assumed. The enzyme, rather than being a simple dimer, may exist in two oligomeric forms consisting of combinations of the subunits strategically interrelated so that the sucrase catalytic site appears to sterically regulate the availability of the isomaltase site (11). A reduction in sucrase activity in rat brush-border membrane vesicles in response to increasing temperature leads to a reciprocal in-

crease in isomaltase activity through recruitment of functional isomaltase catalytic sites.

The glycosylation of SI is similar to other disaccharidase complexes and includes two main steps (Fig. 1); the cotranslational acquisition of glucan units of a high mannose type at the endoplasmic reticulum and the subsequent trimming and complex glycosylation in the Golgi apparatus (12). This results in a mature SI that contains a large proportion of asparagine-linked oligosaccharides made up of sialic acid, galactosamine, N-acetyl galactosamine, and mannose, as well as mucin type O-glycosidic linkage characterized by a bond between an N-acetyl galactosamine residue and a serine or threonine residue on the polypeptide chain (13). The peptide sequence of human SI precursor contains 18 putative N-glycosylation sites (14). Knowledge of the N-glycosylation sites is particularly useful for the study of CSID, where the absence of expression of this enzyme is often associated with a block in its transport and with abnormalities in glycosylation.

Molecular Biology

The gene encoding human SI has been localized to the long arm of chromosome 3 (15,16). A comparison between the human enzyme and SI in the rabbit, rat, and pig shows a high degree of homology of both nucleotide and amino acid sequences in the N-terminal and active site regions (16). An optimal alignment of the two subunits reveals a high degree of homology between the isomaltase and sucrase portions (41% for amino acids and 52% at the DNA level), indicating that SI probably evolved by partial gene duplication (8). In addition, homology




FIG. 1. Cotranslational modification and posttranslational processing of sucrase isomaltase (SI) in the enterocyte organelles and intestinal lumen. SI is synthesized as a long polypeptide chain carrying two similar but not identical active sites (pro-sucrase-isomaltase). The pro-SI is inserted into the rough endoplasmic reticulum (RER) via the same N-terminal hydrophobic region, acting as a targeting protein to the RER, which will later act as the anchor in the brush-border membrane. In the RER, the polypeptide elongates and is glycosylated at asparagine sites (ASN) with mannose (M) residues. The glycoprotein then migrates to the Golgi complex, where mannose residues are trimmed and complex glycosylation with N-acetyl galactosamine (NAG) and sialic acid (SA) residues at ASN and serine (SER) sites takes place. After complex glycosylation, the pro-SI is inserted into the enterocyte membrane, with the sucrase catalytic domain protruding furthest out into the lumen. Pro-SI is then rapidly processed by trypsin, yielding the two subunits of isomaltase and sucrase associated by noncovalent strong ionic interactions.

at the active site indicates that human SI, human lysosomal α -glucosidase, and yeast glucoamylase probably shared an ancestral gene and are only differentiated significantly at the N-terminal regions, accounting for the different biosynthetic pathways and cellular location of these enzymes (17). The SI complex is synthesized by small-intestinal epithelial cells with a noncleavable signal sequence that also contains the membrane anchoring domain. In contrast, the N-terminus of human lysosomal α -glucosidase comprises a signal peptide that is cleaved off, generating a soluble glycoprotein whose final desti-

nation is an intracellular organelle, the lysosome. Southern blotting, sequencing, and mRNA studies indicate that, in comparison with normal small intestine, the structure of the SI gene and its mRNA are unaltered in the two human colon cancer cell lines Caco-2 and HT-29 (14).

Northern blots of RNA extracted from subpopulations of rat and human intestinal epithelial cells that are isolated from villus and crypt compartments show that the cloned gene hybridizes to a 6.5 kb band predominantly in villus RNA (18). RNA probes have localized the greatest accumulation of SI mRNA to the nucleus of cells at the crypt-villus junction. Abundant mRNA is also seen in cells from the lower mid-villus region in both the nucleus and cytoplasm, with a disappearance of nuclear mRNA and a decline in cytoplasmic mRNA from the mid-villus to the tip (19).

Using full-length rabbit and partial human SI cDNA clones as probes, a good correlation has been demonstrated between the expression of SI at the levels of mRNA and protein. Thus, similar to other proteins expressed in enterocytes including liver fatty acid binding protein, cytochrome P450IIB1, and aminopeptidase N, SI is regulated at the level of increasing mRNA abundance as cells migrate from crypt to mid-villus (19). For these reasons, SI is considered a useful marker for enterocyte differentiation. The decrease in sucrase enzymatic activity in villus tip cells has been attributed to enzymatic degradation of the sucrase portion of the dimeric enzyme by luminal pancreatic proteases (20); however, a decrease in the steady-state levels of SI mRNA may also play a role secondary to either a decrease in transcription of the gene or more rapid degradation of cytoplasmic mRNA.

Control of Enzyme Activity (Table 2)

The regulation of oligosaccharidases is a dynamic process since their half-life is only 4–16 h; therefore, maintenance of activity at the brush border requires several cycles of synthesis and degradation during the life cycle of the human intestinal cell. Multiple factors modulate the activity of SI at the level of transcription, translation, glycosylation, and processing by luminal proteases. In addition, factors such as the age of the cell, its degree of differentiation along the villus, and proximal versus distal intestinal location play an important role in determining enzyme activity. Finally, dietary components and circulating hormones may alter the ac-

TABLE 2. Control of sucrase-isomaltase activity at different levels and sites

	Increased activity	Decreased activity
Transcription	Crypt-villus junction	Villus tip
Translation	Jejunum	Jejunum
Glycosylation	Complex	Simple (high-mannose)
Pancreatic proteases	Pancreatic duct obstruction	↑ Pancreatic enzymes
Diet	High-sucrose, high-carbohydrate diet	Fasting, high-protein, low-carbohydrate diet
Hormones	Thyroxine, corticosteroids	

tivity of brush-border enzymes by varying their synthesis or degradation rate.

Both in rabbits and in humans, SI is most likely primarily controlled at the transcriptional level, since the enzyme activities have a high correlation coefficient with the level of SI mRNA (21). The fact that autoradiographic grains representing SI mRNA are first noted over nuclei in cells at the crypt-villus junction and only seen in the cytoplasm as these cells migrate into the mid-villus region further supports the hypothesis that transcription of the sucrase-isomaltase gene is activated (18). The cellular or extracellular factors that signal the nucleus to initiate SI gene transcription are largely unknown. Over 3000 base pairs of the 5' flanking region of the gene are required for high-level expression. Recently, Traber et al. have shown the enterocyte-specific transcription of the gene in mice and humans is controlled by a 183 base pair promoter located immediately upstream of the transcriptional start site (22,23). This promoter contains at least three nuclear protein-binding sites that appear to bind intestine-specific nuclear protein complexes required for transcriptional activity. These protein complexes have not been fully characterized.

Levels of SI activity may be regulated posttranslationally as well as at the mRNA level. Based on results of differential immunohistochemical staining and immunoprecipitation studies, Beaulieu et al. concluded that SI protein is synthesized in both crypt and villus cells, but that there are differences in posttranslational processing of the protein (24). In the rat, there is a three- to fivefold greater activity of SI in the jejunum versus the ileum. Although no differences are found in SI mRNA abundance between the two sites, the relative rate of de novo

synthesis of all forms of the enzyme is three to fivefold greater in the jejunum than the ileum, and a greater proportion of jejunal SI mRNA is associated with membrane-bound polyribosomes, suggesting greater translational efficiency (25).

These results indicate that along the longitudinal axis of the small intestine, SI expression is regulated by differences in translational mechanisms. In the rabbit, the in vitro biosynthesis of SI correlates well with the steady-state levels of its cognate mRNA all along the small intestine; however, the ratio of sucrase activity to SI mRNA is lower in the jejunum versus the ileum, again suggesting that variations in sucrase activity along the intestine are due both to transcriptional and posttranslational events (26).

Changes in glycosylation may be partially responsible for the posttranslational regulation of SI activity. After synthesis of a carbohydrate-free precursor in ribosomes bound to the membrane of endoplasmic reticulum, SI is conjugated to N-linked polmannose chains to form high-mannose glycoproteins. The high-mannose precursor is then transported from the rough endoplasmic reticulum to the Golgi complex, where the addition of complex O-linked oligosaccharide chain takes place, yielding the mature "complex" precursor. The high-mannose form has a substantially lower specific activity than the complex glycosylated form (27). High-mannose glycosylation seems to be essential for proper and timely polypeptide folding of the enzyme, allowing it to escape the endoplasmic reticulum. Fructose rapidly induces a block in the expression of SI and other brush-border membrane glycoproteins. The underlying mechanism involves abnormal high-mannose glycosylation and misfolding of the nascent polypeptide chains, thereby delaying exit from the endoplasmic reticulum and leading to degradation by rapid proteolytic breakdown (28,29). Changes in glucose metabolism may also inhibit the biosynthesis of SI both through a decrease in mRNA levels and an inhibitory effect on the conversion of the high-mannose to the complex glycosylated form. Glucose itself, monensin (when used in concentrations that induce increased glucose consumption), and forskolin through increased glycogenolysis via activation of adenylate cyclase all impair glycosylation of the enzyme (30,31).

After complex glycosylation in the Golgi body and transport to the microvillus membrane in vesicles, insertion and processing of SI to subunits pro-

ceeds via a complex series of cleavage steps mediated by pancreatic trypsin (32). The major cleavage site in humans is located between an arginine and isoleucine residue, yielding the sucrase subunit with isoleucine at its N-terminus. This is a trypsin-specific site that is not attacked by either elastase or chymotrypsin. Pancreatic proteases also participate in the luminal degradation of mature SI and appear to be at least partially responsible for the loss of sucrase activity in mature villus tip cells and in ileal enterocytes. Studies in animal models of pancreatic duct obstruction or bypass have demonstrated a decreased rate of degradation in duct-ligated animals, leading to increased SI activity and a disappearance of the usual proximal to distal gradient of sucrase activity in the small bowel (33-35).

Dietary factors and endogenous hormones are also important regulators of SI activity. SI is an inducible brush-border enzyme; both enzyme activities are increased by feeding a high-sucrose or high-carbohydrate diet and decreased by fasting (36). In rats, the mRNA levels of SI increase rapidly after sucrose force-feeding, and these changes correlate with the corresponding increase in enzyme synthesis, enzyme activity, and amounts of immunoreactive enzyme (37). This rapid increase in mRNA accumulation suggests that sucrose feeding induces an increase in transcription of the gene. Rats fed a high-protein, low-carbohydrate diet develop decreased sucrase activity. This effect appears to be at least partially a consequence of increased degradation of sucrase because it is correlated with marked increases in luminal trypsin activity and accumulation of isomaltase monomer, considered a degradation product of the enzyme (35).

Both thyroxine and glucocorticoids induce the precocious appearance of SI in the rat small intestine, mediated primarily by increases in the abundance of its mRNA (38,39). In humans, the SI complex is expressed in small intestine throughout gestation and in an identical form in the fetal colon between 12 and 30 weeks gestation. Before 30 weeks gestation, the enzyme is present only as the single polypeptide prosucrase-isomaltase; whereas after that time, two subunits are also present (40). Mature active SI is also expressed in adenocarcinoma of the colon and in the human colon carcinoma cell lines, Caco-2 and HT-29 (41). These cell lines have been particularly useful in studying enterocyte differentiation and the factors that regulate gene expression of human disaccharidases.

CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY Molecular Defect

There is abundant phenotypic variation in patients with CSID. All CSID patients lack sucrase, but some have only traces of isomaltase activity, others have reduced but significant isomaltase activity, and still others almost normal activity. The presence of residual isomaltase activity in many patients suggests that CSID is not the consequence of complete absence of SI gene expression. It appears that this phenotypic variation may be mirrored in genotypic heterogeneity. Although specific genetic mutations have not been identified as yet, different molecular defects documented in patients with CSID indicate abnormalities of intracellular processing (glycosylation and folding), intracellular transport, and homing and insertion of the enzyme into the brush-border membrane (Table 3).

It is well known that cellular mutations leading to amino acid substitutions may influence the processing and intracellular transport of glycoproteins (42,43). These point mutations may substantially affect the folding of peptide chains, leading to improper glycosylation. Normal glycosylation of disaccharidases is necessary for the sorting of the enzymes to the brush-border membrane. Tunicamycin, an antibiotic that inhibits N-linked high-mannose glycosylation of proteins, greatly reduces the expression of disaccharidases in brush-border membranes of pig small intestine, leading to rapid intracellular degradation of newly synthesized enzyme (44). Monensin, which allows high-mannose glycosylation but interferes with complex glycosylation of disaccharides in the Golgi body, affects the further transport of the enzyme to the microvillus membrane.

As many as five different transport incompetent or functionally altered enzymes have been discovered in patients with CSID (45) (Table 3). The first molecular phenotype was described by Hauri et al. in 1985 in a 5-year-old girl with no sucrase but low residual intestinal isomaltase activity (46). Immunoelectron microscopy with monoclonal antibodies that reacted specifically with various forms of the prosucrase-isomaltase in biopsy samples from healthy subjects revealed that the enzyme was confined predominantly to the microvillus membrane of enterocytes and there was minimal labeling of the Golgi apparatus. In contrast, in the patient, immunoreactive SI was found almost exclusively in the

TABLE 3. Molecular defects in patients with CSID

	Molecular phenotype				
	I	II	III	IV	V
Location	Golgi	RER	Brush border	Brush border	RER, basolateral membrane
Form	High-mannose precursor	High-mannose and complex precursors	Mature enzyme (catalytically altered sucrase subunit)	Complex precursor (intracellular)	High-mannose precursor
Intracellular degradation products	Present	Present	Absent	Present (sucrase subunit)	?
Microvillus membrane	Absent	Absent	Present (both subunits)	Present (isomaltase subunit only)	Absent
Sucrase activity	0	0	0	0	0
Isomaltase activity	Low	0	Normal	Normal	0

RER, rough endoplasmic reticulum.

Adapted from Sterchi EE, Lentze MJ, Nail HY. Molecular aspects of disaccharidase deficiencies. *Baillieres Clin Gastroenterol* 1990;4:79-96; and from Fransen AM, Hauri HP, Ginsel LA. Naturally occurring mutations in intestinal sucrase-isomaltase provide evidence for the existence of an intracellular sorting signal in the isomaltase subunit. *J Cell Biol* 1991;115:45-57.

Golgi cisternae and associated vesicular structures, with no specific labeling in the microvillus membrane. Immunoprecipitation experiments revealed that the enzyme localized to the Golgi appeared to be the high-mannose form plus lower-molecular-weight degradation products. Subsequently, a second patient was reported with abundant synthesis of a high-mannose SI with arrest of further intracellular processing and failure of a mature glycoprotein form to reach the brush-border membrane (47).

There are several other human diseases associated with disordered intracellular processing of glycoproteins. The intrahepatic accumulation of abnormal glycoprotein in the pIZZ phenotype of α -1-antitrypsin deficiency is related to a single amino acid substitution with subsequent failure to transport the high-mannose secretory product through the endoplasmic reticulum (48).

Further study at the subcellular and protein level of patients with CSID has revealed that the maturation and intracellular transport of the enzyme are blocked at different stages along with biosynthesis pathway (45). In a second molecular phenotype, a high-mannose form of the enzyme is incompletely trimmed and blocked not in the Golgi but in the endoplasmic reticulum. A third phenotype appears to be the result of a mutation affecting only the catalytic site of sucrase; the mature enzyme is found inserted into the brush-border membrane and isomaltase activity is relatively preserved (49). Study of a fourth phenotype reveals variants of pro-sucrase-isomaltase precursors that are converted

from the high-mannose form to the mature complex glycosylated form at a slow rate. The enzyme undergoes intracellular cleavage to two subunits and the sucrase subunit is degraded, whereas the isomaltase subunit is normally transported to the brush border (50). In this patient, isomaltase activity was normal. Finally, a mutant phenotype has been recently described where the mannose-rich polypeptide precursor of the enzyme is normally synthesized but remains in the endoplasmic reticulum, does not undergo terminal glycosylation in the Golgi, and is missorted to the basolateral membrane rather than homing to its normal location in the brush-border membrane (50).

These last two naturally occurring mutations provide evidence that structural features in the isomaltase region of pro-sucrase-isomaltase act as an intracellular sorting signal, allowing for transport from the trans-Golgi network to the brush-border membrane (51). The nature of these structural features and of the intracellular elements that recognize them is not yet known.

There have been several cases of CSID in which no immunoreactive forms of sucrase-isomaltase were observed via immunoprecipitation or electron microscopy either on the brush border or intracellularly (45). These cases may represent a defect in transcriptional regulation of sucrase-isomaltase expression. Alternatively, the enzyme may be synthesized but improperly folded and hence not recognized by the specific monoclonal antibodies used to detect the protein.

Incidence

Congenital sucrase-isomaltase deficiency (CSID) is considered a rare autosomal recessively inherited disease, but it is likely that the prevalence has been underestimated (Table 4). Given the wide phenotypic variation and the probability that a variety of genetic mutations cause CSID of varying severity, it is likely that numerous patients suffering from chronic diarrhea remain undiagnosed. Previous studies have attempted to ascertain the number of heterozygote carriers in the general population based on measurements of sucrase enzyme activity in small-intestinal biopsy specimens. Heterozygotes are defined as those with a level of sucrase activity below the lower limit for the normal population, with ratios of sucrase:lactase activity of <0.9 and with normal small-bowel morphology. Using these criteria, Peterson and Herber estimated the incidence of heterozygotes to be 8.9% of the general population in the United States (52). Welsh et al. found a much lower incidence of ~2% heterozygotes in the Caucasian population (one in 2500 homozygotes according to the Hardy-Weinberg equation) and no case that satisfied these criteria among 53 African Americans tested (53). In Denmark, only one case of CSID was uncovered in over 2000 patients biopsied because of abdominal pain and diarrhea (54). The incidence appears to be much higher in Greenland, Alaskan, and Canadian Eskimos (54-56). In Greenlanders with diarrhea, the incidence of sucrose malabsorption is 10.5% (47). In the general population of Greenland, ~5% of those tested showed very low sucrase activity in small-bowel biopsies, and 12.5% had activity below the lower limit of the control population (2).

Numerous cases have been described of CSID among siblings and parents. Kerry and Townley biopsied parents of four children with CSID and found most of them to have sucrase activities below the lowest values in a control group. Seven of the eight parents had a sucrase:lactase ratio below 0.8 (57). From these data, it seems reasonable to as-

sume that CSID is transmitted via autosomal recessive inheritance.

The previous data on heterozygotes suggests that CSID may be more prevalent than previously believed. A small number of patients with intermittent or persistent diarrhea have been diagnosed in adult life (2,58). Because they have no family history and no history of growth failure or malabsorption, these patients have been assumed to suffer from irritable bowel syndrome.

Pathogenesis

Malabsorption of dietary disaccharides and starch in the proximal small intestine gives rise to an osmotic load that stimulates peristalsis in the ileum and colon. In response to the osmotic pressure difference between blood and lumen, water flows into the permeable jejunum and sodium moves into the lumen down its concentration gradient. The end-result is a large volume of intraluminal isotonic fluid with a normal sodium concentration held within the lumen because of the osmotic pressure generated by the malabsorbed carbohydrate solute. When the capacity of colonic bacteria to ferment malabsorbed carbohydrate and the ability of the colonocyte to absorb fluid and the resulting short-chain fatty acids is overwhelmed, diarrhea ensues.

Unabsorbed carbohydrates present in the distal small intestine have effects on distant gastrointestinal functions and the absorption of other nutrients as well (59). They inhibit gastric emptying and accelerate small-intestinal transit because of a decrease in water and sodium absorption. Accelerated duodenal and small-bowel transit may also contribute to the malabsorption of starch, fat, or even monosaccharides. Malabsorption of oligo- and monosaccharides may lead to disruption of the normal postprandial surge of hormones such as insulin, C-peptide, and gastric inhibitory peptide (60).

CSID is not invariably associated with severe diarrhea. Whether sugar or starch malabsorption produces symptoms depends not only on the residual enzyme activity, but also on additional factors such as the quantity of ingested carbohydrate, the rate of gastric emptying, the effect on small-bowel transit, the metabolic activity of colonic bacteria, and the absorptive capacity of the colon. For many of these parameters, the infant is at a disadvantage compared to the adult; this undoubtedly contributes to the increased severity of symptoms seen in many

TABLE 4. Prevalence of CSID in various populations

Group	Percentage
Greenland Eskimos	2-10%
Native Alaskans	3.0%
Canadian native peoples	3.6-7.1%
Danes	<0.1%
North Americans	<0.2%

Data compiled from references (2), (52-57).

infants with CSID. In infants, the length of the small intestine is shorter and the reserve capacity of the colon to absorb excess luminal fluid is reduced compared to adults. Some infants may be consuming a high-carbohydrate diet in the form of juices, baby food fruits and vegetables, and cereals. In young infants with carbohydrate malabsorption, small-intestinal and colonic transit is likely to be more rapid, allowing less time for alternative paths of carbohydrate digestion, including the salvage of malabsorbed carbohydrate by colonic bacterial fermentation.

Compensatory mechanisms for starch digestion limit the diarrheagenic effects of starch malabsorption in patients with CSID. Isomaltase activity is often low but not necessarily absent in these patients. Most starch consumed by young patients has a low content of α -1-6 glucosyl bonds, and the residual isomaltase may be sufficient to hydrolyze these linkages. Glucoamylase activity is normal or increased and is still sufficient to ensure the adequate digestion of the α -1:4 bonds of amylopectin. In addition, the capacity of colonic bacteria to ferment starch is usually well developed in infants by 6 months of age (61,62).

Clinical Presentation

The clinical presentation of CSID is variable; in part, it depends on the introduction of sucrose into the diet. Breast-fed babies or infants consuming lactose-containing formulas will not manifest symptoms until they ingest juices, solid foods, or medications sweetened by sucrose. Baby cereals usually cause less severe symptoms because of the compensatory mechanisms for starch digestion.

Table 5 summarizes the presenting symptoms in 23 patients with CSID. There is an even sex distribution but an overwhelming predilection for Caucasians to be affected, with only one Hispanic patient

and no African Americans diagnosed. In only two instances is there a family history, with two affected sisters and a father and son among the group studied. Chronic watery diarrhea and failure to thrive are common findings in infants and toddlers (63). Other nonspecific findings in this age group include abdominal distention, gassiness, colic, irritability, excoriated buttocks, diaper rash, and (at times) vomiting. Half the patients were diagnosed after the age of 5 years with long histories of chronic diarrhea and abdominal pain.

A minority of severely affected patients require hospitalization for diarrhea and dehydration, malnutrition, muscle wasting, and weakness (64). Often, the correct diagnosis is delayed while other causes of severe chronic diarrhea are entertained (65). These infants may be presumed to have cow's milk or soy protein allergy and often are subject to multiple formula changes. An improvement in symptoms while ingesting a casein-hydrolysate formula may be interpreted as support for this mistaken diagnosis when in truth it reflects the switch in carbohydrate to glucose polymers, which are more dependent on glucoamylase activity for intraluminal digestion. Other diagnoses often considered are cystic fibrosis, celiac disease, severe viral gastroenteritis, or other causes of intractable diarrhea. Support for these possibilities may come from the mild steatorrhea documented in some patients (2). This finding is thought to be due to rapid intestinal transit or chronic malnutrition with partial villus atrophy. Transient hypoglycemia, acidosis, dehydration, and lethargy may lead to consideration of inborn errors of metabolism.

A delay in the diagnosis may also be related to empiric institution of a low-sucrose diet by the parents. Some children attain relatively normal growth and manifest chronic symptoms of intermittent diarrhea, bloating, and abdominal cramps (Table 5). As toddlers, they may be considered to have chronic, nonspecific diarrhea of childhood (66) and are often not diagnosed until the age of 5 years. In older children, symptoms of crampy abdominal pain, gas, and intermittent diarrhea suggest irritable bowel syndrome. Institution of a diet for these conditions including the avoidance of fruit juices, soft drinks, and fructose- and sorbitol-containing beverages and fruits may actually ameliorate symptoms by simultaneously reducing the sucrose load in the diet.

In some societies, dietary habits may mask symptoms. Up until recently, Greenland Eskimos con-

TABLE 5. Presenting symptoms in 23 patients with CSID

Symptoms	Frequency	Mean age at diagnosis (yr)
Chronic diarrhea and failure to thrive	7/23	2.0 \pm 1.1
Chronic diarrhea with normal growth	9/23	5.6 \pm 3.5
Irritable bowel syndrome, abdominal pain	7/23	15.4 \pm 7.3

sumed low-carbohydrate, high-protein, high-fat diets. Only recently has the sugar content of their diet reached European levels (2,54,64). Of 20 Greenland Eskimos diagnosed by McNair et al. with CSID in 1972, seven were adults who denied any gastrointestinal symptoms, presumably as a result of their low-sucrose diet (67). In spite of the various ages and symptoms at presentation of patients with CSID shown in Table 5, there was no difference in the intestinal levels of sucrase-isomaltase or maltase activity measured from small-bowel biopsies in any of these groups.

CSID has been diagnosed in adult patients (58,68, 69). Many adults with CSID give a history of feeding difficulties during their infancy and intermittent symptoms since childhood (58,63). Occasionally, the symptoms appear as late as the time of puberty (69). In these patients, the underlying enzyme deficiency can be unmasked by an enteric infection. The symptoms that persist in adult life may be limited to some increase in bowel frequency and to abdominal distention and flatulence, especially at the end of the day, although episodic watery diarrhea associated with large sucrose intake still occurs. In a few patients, diarrhea has alternated with constipation, causing further confusion with irritable bowel syndrome. Some investigators have noted a tendency for spontaneous improvement of symptoms with age; in particular, the starch tolerance seems to improve (1). Possible explanations for these observations include self-regulation of the diet to limit sucrose ingestion and an adaptive increase in colonic salvage of carbohydrate through the stimulatory effects of chronic carbohydrate malabsorption on the fermentative activity of colonic flora.

Diagnostic Evaluation

Several diagnostic tests are available; each has its advantages and pitfalls. An excess of reducing substances ($>0.5\%$) may be demonstrated in liquid stool from a patient with CSID provided the fecal sucrose is hydrolyzed by boiling with 0.1 N HCl. The pH of the stools in a patient with CSID classically should fall between 5.0 and 6.0. Both of these tests have a high degree of false-negative results (70). The presence of sucrose in fecal effluent can also be sensitively detected by paper chromatography.

Prior to the advent of hydrogen breath tests, oral sucrose tolerance tests were the mainstay of the

noninvasive diagnosis of CSID. In children, a rise in blood glucose of >20 mg/dl after a 2.0 g/kg sucrose load is considered an indication of sucrose malabsorption. However, there is a high incidence of false-positive tests (flat sucrose tolerance curve) due to delayed gastric emptying, which can only be verified by intraduodenal instillation of the sucrose load (71).

Sucrose Breath Tests

Sucrose breath hydrogen tests have been extensively validated in children with sucrose malabsorption and normal controls (72). In normal sucrose-tolerant subjects given a 1.0–2.0 g/kg oral sucrose load (≤ 50 g), the change in breath hydrogen excretion over baseline is <10 parts per million. Two previous studies of children with CSID have shown an elevation of breath hydrogen >20 parts per million over baseline between 90 and 180 min after the ingestion of sucrose (72,73).

False negatives can occur with this test (74). Of 23 patients studied, we have documented that our two youngest patients with CSID (both 10 months of age) and one 10-year-old patient failed to show elevated breath hydrogen excretion over a 3-h period when given oral sucrose (2 g/kg sucrose up to 50 g). These patients appear to be non-hydrogen producers; this hypothesis can be confirmed by conducting a breath hydrogen test with a nonabsorbable carbohydrate substrate such as lactulose.

The prevalence of non-hydrogen producers has been estimated to be 2–20% of the general population (75–78). However, recent data have suggested that this figure is an overestimation and that most subjects will produce small amounts of hydrogen in response to malabsorbed carbohydrate if the test is extended beyond 3 h (79). A delay in gastric emptying of a concentrated sucrose load might prolong the transit of malabsorbed sucrose to the cecum in some patients with CSID. Another potential confounder is the acid milieu that may exist in the colon of patients with chronic sucrose and starch malabsorption. Reduction of colonic intraluminal pH secondary to chronic lactulose ingestion has been shown to significantly reduce the intracolonic production of hydrogen (80). A chronically low pH in the colon of patients with CSID may mask the expected rise in colonic hydrogen production and breath hydrogen excretion.

These potential pitfalls suggest that care must be taken in the interpretation of sucrose breath hydro-

gen tests in patients with potential CSID. First, it is important to monitor the symptoms and stool pattern of such patients for 24 h after the breath test is done. Patients who experience significant diarrhea and other symptoms in spite of "negative" sucrose breath hydrogen tests should be screened by other methods. Second, obtaining breath hydrogen determinations for up to 4 h after the ingestion of sucrose may enhance the sensitivity of the test. Third, insistence on a change in breath hydrogen excretion of >20 parts per million over baseline may exclude some patients with CSID, especially if the sucrose load ingested is <1 g/kg. Finally, an unrestricted diet prior to administration of the sucrose breath test may mask a positive test by lowering the intracolonic pH and limiting hydrogen production.

Differential Urinary Disaccharides

Following ingestion, a small fraction of intact disaccharide diffuses unmediated across the intestinal mucosa. The exact quantity is determined by absorptive area, permeability, rate of intestinal transit, and factors controlling intraluminal concentration, such as dilution and rate of hydrolysis. Because most absorbed disaccharides are completely and rapidly excreted into urine, the fraction of an ingested dose excreted in the urine is determined by the gastrointestinal factors described, provided renal function is normal. When lactulose, which resists mucosal hydrolysis, is ingested together with a hydrolyzable test disaccharide such as sucrose, correction for variables other than hydrolysis is obtained and the sucrose:lactulose ratio specifically indicates the corresponding mucosal sucrase activity. Active hydrolysis of sucrose or isomaltose results in calculated ratios >0.3 , whereas the absence of SI produces ratios of these disaccharides to lactulose approaching one (81,82). In practice, this test of differential urinary disaccharide excretion consists of administering simultaneous lactulose, lactose, isomaltose, and sucrose after an overnight fast and then collecting urine for 10 h. After recording the urinary volume, an aliquot is analyzed by quantitative paper or thin-layer chromatography for the sugars tested.

Using this method, Maxton et al. have demonstrated excellent agreement between differential urinary disaccharide excretion and small-intestinal disaccharide determinations in patients with CSID (81,82). The addition of rhamnose to the test sugars allows the calculations of a urinary lactulose:rham-

nose ratio, which has been shown to be a useful index of intestinal mucosal permeability (83). CSID is associated with normal mucosa and normal permeability. It can therefore be distinguished from disaccharidase deficiency secondary to diffuse small-intestinal disease, in which the lactulose:rhamnose permeability would be expected to be increased. This test appears to offer a noninvasive method of assessing the activity of multiple intestinal disaccharidases and mucosal permeability simultaneously.

Intestinal Disaccharidases

Measurement of intestinal disaccharidases has remained the gold standard for the diagnosis of CSID. A small-bowel biopsy obtained either with a capsule placed in the proximal jejunum or with the endoscope in the second or third portion of the duodenum will provide material not only for enzyme activity determinations but for histological examination as well. At least two biopsy specimens taken via a standard upper endoscope and three biopsy specimens taken with the pediatric upper endoscope should be obtained for disaccharidase determinations. The mucosa is usually normal histologically, but some patients with severe malnutrition may show mild partial villous atrophy.

In spite of the various ages and symptoms at presentation of the patients summarized in Table 5, sucrase activity is either completely or almost completely absent in 15 of 20 patients tested, isomaltase activity is markedly reduced in 14 of 20 tested, and maltase activity is reduced by 60–90% in 18 of 20 tested. Glucoamylase activity is usually normal, accounting for the residual measured maltase activity (5). In some cases, a reduction of the measured amount of glucoamylase activity has been observed (84). Lactase and alkaline phosphatase levels should be normal.

It is important to ascertain the location of small-bowel biopsy specimens when interpreting intestinal disaccharidase levels. Simultaneous biopsies of the proximal jejunum and the second portion of the duodenum in the patients with histologically normal mucosa and normal disaccharidases have shown a 30–40% reduction in lactase, sucrase, and maltase activity in the duodenum compared to the jejunum (85,86). This finding does not appear to be the result of a sampling error since it is in agreement with disaccharidase determinations in intestinal resection specimens (53,87). Most endoscopic small-

bowel biopsy specimens are obtained from the duodenum; however, much of the published normative data for intestinal disaccharidases comes from tissue obtained from the jejunum with a Crosby capsule (88,89).

Sucrase-isomaltase deficiency is defined as the reduction of enzyme activities to levels lower than at least two standard deviations below the mean for biopsy specimens from normal patients with normal small-bowel histology. Combining the actual measured values of sucrase, isomaltase (palatinase), maltase, and lactase activities with the sucrase:lactase ratio can increase the diagnostic accuracy of the test for CSID. Provided the patient does not have primary lactase deficiency or secondary disaccharidase deficiency from partial or total villous atrophy, the normal sucrase:lactase ratio in adults is 1.9 ± 0.2 (mean \pm SEM) when the biopsy specimen is obtained from the duodenum and 1.6 ± 0.2 when it is taken from the proximal jejunum (85). This ratio should decrease in children <3 years of age since among young children with normal small-bowel histology, lactase levels are generally increased compared to older children whereas sucrase activity remains constant (88). However, the ratio should never be <1.0 unless there is isolated decreased sucrase-isomaltase activity; it should actually increase in primary lactase deficiency or diffuse small-bowel injury and secondary disaccharidase deficiency, where lactase levels are usually more severely depressed than SI activity.

Treatment

Currently, the treatment of CSID consists of life-long adherence to a strict sucrose-free diet. It is seldom necessary to make the diet starch-free as well except in infants, or in older children in whom the institution of a sucrose-free diet does not lead to prompt disappearance of symptoms. In this case, the starch content of the diet must be reduced with special attention to foods having a high amylopectin content, such as wheat and potatoes (2). Compliance with this diet is difficult, and there appears to be a high incidence of chronic gastrointestinal complaints, decreased weight for height, and decreased weight for age in patients with CSID followed after diagnosis (63,64,90). Neither sucrose nor fructose, both of which are known to stimulate sucrase and maltase activity when ingested by normal adults, have been shown to induce enzyme activity in pa-

tients with CSID. There is no evidence that deficient SI activity increases with age.

Enzyme substitution therapy has recently been applied to patients with CSID. A study of eight children with CSID showed that a small amount of lyophilized baker's yeast (*Saccharomyces cerevisiae*) eliminated or lessened symptoms of diarrhea, cramps, or bloating, and also lowered breath hydrogen when administered with an oral sucrose load (91). However, baker's yeast is not palatable in this form and is poorly accepted, especially by young children. As a by-product of the manufacture of belt-dried baker's yeast, a liquid preparation containing high concentrations of yeast-derived invertase (sucrase) is obtained. Invertase is a β -fructofuranosidase and cleaves only sucrose having no effect on maltooligosaccharides. In vitro, it is extremely potent, stable with refrigeration, and tasteless when mixed with water (92). It is also relatively resistant to changes in pH even at levels approximating the intragastric environment. Degradation by pepsin appears to be prevented by buffering intragastric pH and taking the enzyme with food to provide other potential protein substrates for pepsin activity (92).

Recently, 14 patients with CSID were treated with liquid yeast sucrase. Breath hydrogen excretion was significantly reduced in response to a sucrose load, and symptoms of diarrhea, abdominal pain, and gas were prevented or ameliorated in patients consuming a sucrose-containing diet. Improvement in symptoms correlated well with increasing concentrations of the enzyme supplement (92). These results suggest that liquid yeast sucrase may allow the consumption of a more normal diet by children with CSID and decrease the high incidence of chronic gastrointestinal complaints. Secondary sucrase deficiency caused by celiac disease, severe viral or parasitic gastrointestinal infections, the acquired immunodeficiency syndrome, or the short-bowel syndrome may also be amenable to treatment with liquid yeast sucrase.

Acknowledgment: This work was supported in part by a grant from the Orphan Drug Development Office of the Food and Drug Administration (FD-R-000854-01-1). Invaluable help with clinical and laboratory studies was provided by Dr. Naheed Ahsan and Geri Kastoff, M.S., R.D. I also thank Ms. Sandra Hale for preparation of the manuscript.

REFERENCES

1. Auricchio S. Genetically determined disaccharidase deficiencies. In: Walker WA, Durie RR, Hamilton JR et al., eds.

Pediatric gastrointestinal disease: pathophysiology, diagnosis, management. Philadelphia: BC Decker, 1991:647-67.

- Gundmand-Hoyer E, Krasilnikoff PA, Skovborg H. Sucrose-isomaltose malabsorption. In: Draper H, ed. *Advances in nutritional research*; vol 6. New York: Plenum Press, 1984:233-69.
- Semenza G. Anchoring and biosynthesis of stalked brush border membrane proteins: glycosidases and peptidases of enterocytes and renal tubuli. *Annu Rev Cell Biol* 1986;2:255-313.
- Gray GM, Lally BC, Conklin KA. Action of intestinal sucrase-isomaltase and its free monomers on an α -limit dextrin. *Eur J Biochem* 1979;254:6038-43.
- Kelly JJ, Alpers DH. Properties of human intestinal glucoamylase. *Biochim Biophys Acta* 1973;315:113-20.
- Skovborg H. Immunoelectrophoretic studies on human small intestinal brush border proteins: the longitudinal distribution of peptidases and disaccharidases. *Clin Chim Acta* 1981;112:205-12.
- Cogoli A, Mosimann H, Vock C, von Balthazar AK, Semenza G. A simplified procedure for the isolation of the sucrase-isomaltase complex from rabbit intestine. Its amino-acid and sugar composition. *Eur J Biochem* 1972;30:7-14.
- Hunziker W, Spiess M, Semenza G, Lodish HF. The sucrase-isomaltase complex: primary structure, membrane-orientation, and evolution of a stalked, intrinsic brush border protein. *Cell* 1986;46:227-34.
- Hegner M, Kieckebusch-Gück A, Falchetto R, James P, Semenza G, Mantei N. Single amino acid substitutions can convert the uncleaved signal-anchor of sucrase-isomaltase to a cleaved signal sequence. *J Biol Chem* 1992;267:16928-33.
- Naim HY, Sterchi EE, Lentze MJ. Biosynthesis of human sucrase-isomaltase complex. *J Biol Chem* 1988;262:7242-53.
- Zhu JS, Conklin KA, Scheving LA, Smith AJ, Gray GM. Structural and functional correlates of sucrase- α -dextrinase in intact brush border membranes. *Biochemistry* 1991;30:10399-407.
- Roth J. Subcellular organization of glycosylation in mammalian cells. *Biochim Biophys Acta* 1987;906:405-36.
- Hauri HP, Sterchi EE, Bienz D, Fransen JAM, Marxer A. Expression and intracellular transport of microvillus membrane hydrolases in human intestinal epithelial cells. *J Cell Biol* 1985;101:838-51.
- Chantret I, Lacasa M, Chevalier G, et al. Sequence of the complete cDNA and 5' structure of the human sucrase-isomaltase gene. *J Biochem* 1992;285:915-23.
- West LF, Davis MB, Green FR, Lindenbaum RH, Swallow DM. Regional assignment of the gene coding for human sucrase-isomaltase to chromosome 3q25-26. *Ann Hum Genet* 1988;52:57-61.
- Green F, Edwards Y, Hauri HP, et al. Isolation of a cDNA probe for a human jejunal brush-border hydrolase, sucrase-isomaltase, and assignment of the gene locus to chromosome 3. *Gene* 1987;57:101-10.
- Naim HY, Niermann T, Kleinhans U, Hollenberg CP, Srassner AWM. Striking structural and functional similarities suggest that intestinal sucrase-isomaltase, human lysosomal α -glucosidase and *Schwanniomyces occidentalis* glucoamylase are derived from a common ancestral gene. *FEBS Lett* 1991;294:109-12.
- Traber PG, Yu L, Wu GD, Judge TA. Sucrase-isomaltase gene expression along crypt-villus axis of human small intestine is regulated at level of mRNA abundance. *Am J Physiol* 1992;262:G123-30.
- Traber PG. Regulation of sucrase-isomaltase gene expression along the crypt-villus axis of rat small intestine. *Biochim Biophys Res Commun* 1990;173:765-73.
- Goda T, Quaroni A, Koldovsky O. Characterization of degradation process of sucrase-isomaltase in rat jejunum with monoclonal-antibody-based enzyme-linked immunosorbent assay. *Biochem J* 1988;250:41-6.
- Sebastio G, Hunziker V, O'Neill B, Malo C, Menard D. The biosynthesis of intestinal sucrase-isomaltase in human embryo is most likely controlled at the level of transcription. *Biochem Biophys Res Commun* 1987;149:803-39.
- Wu GD, Wang W, Traber PG. Isolation and characterization of the human sucrase-isomaltase gene and demonstration of intestine-specific transcriptional elements. *J Biol Chem* 1992;267:7863-70.
- Traber PG, Wu GD, Wang W. Novel DNA-binding proteins regulate intestine-specific transcription of the sucrase-isomaltase gene. *Mol Cell Biol* 1992;12:3614-27.
- Beaulieu JF, Nichols B, Quaroni A. Post-transitional regulation of sucrase-isomaltase expression in intestinal crypt and villus cells. *J Biol Chem* 1989;264:20000-11.
- Hoffman LA, Chang EB. Determinants of regional sucrase-isomaltase expression in adult rat small intestine. *J Biol Chem* 1991;266:21815-20.
- Keller P, Zwicker E, Mantei N, Semenza G. The levels of lactase and of sucrase-isomaltase along the rabbit small intestine are regulated both at the mRNA level and posttranslationally. *FEBS Lett* 1992;313:265-9.
- Sjöström H, Norén O, Danielsen EM. Enzymatic activity of "high mannose" glycosylated forms of intestinal microvillar hydrolases. *J Pediatr Gastroenterol Nutr* 1985;4:980-3.
- Danielsen EM. Post-translational suppression of expression of intestinal brush border enzymes by fructose. *J Biol Chem* 1989;264:13726-9.
- Danielson EM. Folding of intestinal brush border enzymes. Evidence that high-mannose glycosylation is an essential early event. *Biochemistry* 1992;31:2266-72.
- Chantret I, Trugnan G, Dussaux E, Zwiebaum A, Rousset M. Monensin inhibits the expression of sucrase-isomaltase in Caco-2 cells at the mRNA level. *FEBS Lett* 1988;235:125-8.
- Rousset M, Chantret I, Darmoul D, et al. Reversible forskolin-induced impairment of sucrase-isomaltase mRNA levels, biosynthesis, and transport to the brush border membrane in Caco-2 cells. *J Cell Physiol* 1989;141:627-35.
- Shapiro GL, Bulow SD, Conklin KA. Postinsertional processing of sucrase- α -dextrinase precursor to authentic subunits: multiple step cleavage by trypsin. *Am J Physiol* 1991;261:G847-57.
- Riby JE, Kretchmer N. Participation of pancreatic enzymes in the degradation of intestinal sucrase-isomaltase. *J Pediatr Gastroenterol Nutr* 1985;4:971-9.
- Shinohara H, Goda T, Takase S. Degradation of sucrase-isomaltase in the ileum in jejunum-bypassed rats. *J Biochem* 1991;276:563-6.
- Goda T, Raul F, Gosse F, Koldovsky O. Effects of a high protein, low carbohydrate diet on degradation of sucrase-isomaltase in rat jejunum. *Am J Physiol* 1988;254:907-12.
- Goda T, Koldovsky O. Dietary regulation of small intestinal disaccharidases. *World Rev Nutr Diet* 1988;57:275-329.
- Broyart JP, Hugot JP, Perret C, Porteu A. Molecular cloning and characterization of a rat intestinal sucrase-isomaltase cDNA. Regulation of sucrase-isomaltase gene expression by sucrose feeding. *Biochim Biophys Acta* 1990;1087:61-7.
- Yeh KY, Yeh M, Holt PR. Differential effects of thyroxine and cortisone on jejunal sucrase expression in suckling rats. *Am J Physiol* 1989;256:604-12.
- Leeper LL, Henning SJ. Development and tissue distribution of sucrase-isomaltase mRNA in rats. *Am J Physiol* 1990;258:52-8.
- Triadou N, Zwiebaum A. Maturation of sucrase-isomaltase complex in human fetal small and large intestine during gestation. *Pediatr Res* 1985;19:136-8.

41. Wiltz O, O'Hara CJ, Steele GD, Mercurio AM. Expression of enzymatically active sucrase-isomaltase is a ubiquitous property of colon adenocarcinomas. *Gastroenterology* 1991; 100:1266-78.
42. Tufaro F, Snider MD, McKnight SL. Identification and characterization of a mouse cell mutant defective in intracellular transport of glycoproteins. *J Cell Biol* 1987;105:647-57.
43. Tartakof AM. Mutations that influence the secretory path in animal cells. *Biochem J* 1983;216:1-9.
44. Elbein AD. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. *Annu Rev Biochem* 1987; 56:497-534.
45. Sterchi EE, Lentze MJ, Naim HY. Molecular aspects of disaccharidase deficiencies. *Baillieres Clin Gastroenterol* 1990;4:79-96.
46. Hauri HP, Roth J, Sterchi EE, Lentze MJ. Transport to cell surface of intestinal sucrase-isomaltase is blocked in the Golgi apparatus in a patient with congenital sucrase-isomaltase deficiency. *Proc Natl Acad Sci USA* 1985;82: 4423-7.
47. Lloyd ML, Olsen WA. A study of the molecular pathology of sucrase-isomaltase deficiency. *N Engl J Med* 1987;316: 438-42.
48. Verbanac KM, Heath EC. Biosynthesis, processing and secretion of M and Z variant human α -antitrypsin. *J Biol Chem* 1986;261:9979-89.
49. Naim HY, Roth J, Sterchi EE, et al. Sucrase-isomaltase deficiency in humans. *J Clin Invest* 1988;82:667-79.
50. Fransen JAM, Hauri HP, Ginsel LA, Naim HY. Naturally occurring mutations in intestinal sucrase-isomaltase provide evidence for existence of an intracellular sorting signal in the isomaltase subunit. *J Cell Biol* 1991;115:45-57.
51. Mattei K, Brauchbar M, Bucher K, Hauri HP. Sorting of endogenous plasma membrane proteins occurs from two sites in cultured human intestinal epithelial cells (Caco-2). *Cell* 1990;60:429-37.
52. Peterson ML, Herber R. Intestinal sucrase deficiency. *Trans Assoc Am Physicians* 1967;80:275-83.
53. Welsh JD, Poley JS, Bhatia M, Stevenson DE. Intestinal disaccharidase activities in relation to age, race and mucosal damage. *Gastroenterology* 1978;75:847-55.
54. Gudmand-Höyer E, Fenger HJ, Kern-Hansen P, Rorbaek-Madsen P. Sucrase deficiency in Greenland. *Scand J Gastroenterol* 1987;22:24-8.
55. Bell RR, Draper HH, Bergan JG. Sucrose, lactose, and glucose tolerance in northern Alaskan Eskimos. *Am J Clin Nutr* 1973;26:1185-90.
56. Ellestad-Sayad JJ, Haworth JC, Hildes JA. Disaccharide malabsorption and dietary patterns in two Canadian Eskimo communities. *Am J Clin Nutr* 1978;31:1473-8.
57. Kerrey KR, Townley RRW. Genetic aspects of intestinal sucrase-isomaltase deficiency. *Aust Paediatr J* 1965;1:223-35.
58. Ringrose R, Preiser H, Welsh JD. Sucrase-isomaltase (palatinase) deficiency diagnosed during adulthood. *Dig Dis Sci* 1980;25:384-7.
59. Goda T, Bustamante S, Edmond J, Grimes J, Koldovsky O. Precocious increase of sucrase activity by carbohydrates in the small intestine of suckling rats. II. Role of digestibility of sugars, osmolality and stomach evacuation in producing diarrhea. *J Pediatr Gastroenterol Nutr* 1985;4:634-8.
60. Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology* 1986;91:41-8.
61. Auricchio S, Della Pietra D, Vegente A. Studies on intestinal digestion of starch in man. II. Intestinal hydrolysis of amylopectin in infants and children. *Pediatrics* 1967;39:853-62.
62. Midtvedt AC, Carlstedt-Duke B, Norin KE, Saxerholt H, Midtvedt T. Development of five metabolic activities associated with the intestinal microflora of healthy infants. *J Pediatr Gastroenterol Nutr* 1988;7:559-67.
63. Antonowicz I, Lloyd-Still MB, Skaw KT, Schwachman H. Congenital sucrase-isomaltase deficiency. *Pediatrics* 1972; 49:847-53.
64. Gudmand-Höyer E. Sucrose malabsorption in children: a report of thirty-one Greenlanders. *J Pediatr Gastroenterol Nutr* 1985;4:873-7.
65. Ament ME, Perera DR, Esther LJ. Sucrase-isomaltase deficiency—a frequently misdiagnosed disease. *J Pediatr* 1973; 83:721-7.
66. Treem WR. Chronic non-specific diarrhea of childhood. *Clin Pediatr* 1992;31:413-20.
67. McNair A, Gudmand-Höyer E, Jarnum S, Orrild L. Sucrase malabsorption in Greenland. *Br Med J* 1972;2:19-21.
68. Cooper BT, Scott J, Hopkins J, Peters TJ. Adult onset sucrase-isomaltase deficiency with secondary disaccharidase deficiency resulting from severe dietary carbohydrate restriction. *Dig Dis Sci* 1983;28:473-7.
69. Sonntag WB, Brill ML, Troyer WC, Welsh JD, Semenza G, Prader A. Sucrose-isomaltose malabsorption in an adult woman. *Gastroenterology* 1964;47:18-25.
70. Soeparto P, Stobo EA, Walker-Smith JA. Role of chemical examination of the stool in diagnosis of sugar malabsorption in children. *Arch Dis Child* 1972;47:56-61.
71. Krasilnikoff PA, Gudmand-Höyer E, Moltke HH. Diagnostic value of disaccharide tolerance tests in children. *Acta Paediatr Scand* 1975;64:693-8.
72. Perman JA, Barr RG, Watkins JB. Sucrose malabsorption in children: non-invasive diagnosis by interval breath hydrogen determination. *J Pediatr* 1978;93:17-22.
73. Ford RPK, Barnes GL. Breath hydrogen test and sucrase-isomaltase deficiency. *Arch Dis Child* 1983;58:595-7.
74. Gardiner AJ, Tarlow MJ, Symonds J, Hutchinson JGP, Sutherland IT. Failure of the hydrogen breath test to detect primary sugar malabsorption. *Arch Dis Child* 1981;56:368-72.
75. Bond JH, Levitt MD. Use of breath hydrogen (H_2) in the study of carbohydrate absorption. *Am J Dig Dis* 1977;22: 379-82.
76. Saltzberg DM, Levine MG, Lubar C. Impact of age, sex, race and functional complaints on hydrogen (H_2) breath test in school children. *Arch Dis Child* 1985;60:333-7.
77. Douwes AC, Schaap C, Van Der Klei-Van Moorsel JM. Hydrogen breath test in school children. *Arch Dis Child* 1985; 60:333-7.
78. Joseph F, Rosenberg AJ. Breath hydrogen testing: diseased versus normal patients. *J Pediatr Gastroenterol Nutr* 1988; 7:787-8.
79. Strocchi A, Corazza G, Ellis CJ, Gasbarrini G, Levitt MD. Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H_2 criteria. *Gastroenterology* 1993;105:1404-10.
80. Perman JA, Modler S, Olsen AC. Role of pH in production of hydrogen from carbohydrates by colonic bacterial flora. *J Clin Invest* 1981;67:643-50.
81. Maxton DG, Catt SD, Menzies IS. Intestinal disaccharidases assessed in congenital asucrasia by differential urinary disaccharide excretion. *Dig Dis Sci* 1989;34:129-31.
82. Maxton DG, Catt SD, Menzies IS. Combined assessment of intestinal disaccharidases in congenital asucrasia by differential urinary disaccharide excretion. *J Clin Pathol* 1990;43: 406-9.
83. Noone C, Menzies IS, Banatvala JE, et al. Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis, assessed simultaneously by non-invasive differential sugar permeation. *Eur J Clin Invest* 1986;16:217-25.

84. Skovbjerg H, Krasilnikoff P. Maltase-glucoamylase and residual isomaltase in sucrose intolerant patients. *J Pediatr Gastroenterol Nutr* 1986;5:365-71.
85. Smith JA, Mayberry JE, Ansell ID, Long RG. Small bowel biopsy for disaccharidase levels: evidence that endoscopic forceps biopsy can replace the Crosby capsule. *Clin Chim Acta* 1989;183:317-22.
86. Jönsson KA, Bodenmair G, Tagesson C, Whalan A. Variation of disaccharidase activities in duodenal biopsy specimens. *Scand J Gastroenterol* 1986;21:51-4.
87. Triadou N, Bataille J, Schmitz J. Longitudinal study of the human intestinal brush border membrane proteins. Distribution of the main disaccharidases and peptidases. *Gastroenterology* 1983;85:1326-32.
88. Heitlinger LA, Rossi TM, Lee PC, Lebenthal E. Human intestinal disaccharidase concentrations: correlations with age, biopsy technique, and degree of villous atrophy. *J Pediatr Gastroenterol Nutr* 1991;12:204-8.
89. Calvin RT, Klish WJ, Nichols BL. Disaccharidase activities, jejunal morphology and carbohydrate tolerance in children with chronic diarrhea. *J Pediatr Gastroenterol Nutr* 1985;4:949-53.
90. Kilby A, Burgess EA, Wigglesworth S, Walker-Smith JA. Sucrase-isomaltase deficiency: a follow-up report. *Arch Dis Child* 1978;53:677-9.
91. Harms HK, Bertele-Harms RM, Bruer Kleis D. Enzyme substitution therapy with yeast *Saccharomyces cerevisiae* in congenital sucrase-isomaltase deficiency. *N Engl J Med* 1987;316:1306-9.
92. Treem WR, Ahsan N, Sullivan B, et al. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. *Gastroenterology* 1993;105:1061-8.

30. Chantret I, Lacasa M, Chevalier G, et al. Sequence of the complete cDNA and the 5' structure of the human sucrase-isomaltase gene. Possible homology with a yeast glucoamylase. *Biochem J* 1992; 285:915–23.

31. Nichols BL, Eldering J, Avery S, et al. Human small intestinal maltase-glucoamylase cDNA cloning. Homology to sucrase-isomaltase. *J Biol Chem* 1998;273:3076–81.

32. Nichols BL, Avery S, Sen P, et al. The maltase-glucoamylase gene: common ancestry to sucrase-isomaltase with complementary starch digestion activities. *Proc Natl Acad Sci U S A* 2003;100:1432–7.

33. Quezada-Calvillo R, Robayo-Torres C, et al. Luminal substrate “brake” on mucosal maltase-glucoamylase activity regulates total rate of starch digestion to glucose. *J Pediatr Gastroenterol Nutr* 2007;45:32–43.

34. Quezada-Calvillo R, Sim L, Ao Z, et al. Luminal starch substrate “brake” on maltase-glucoamylase activity is located within the glucoamylase subunit. *J Nutr* 2008;138:685–92.

35. Quezada-Calvillo R, Robayo-Torres C, Opeku AR, et al. Contribution of mucosal maltase-glucoamylase activities to mouse small intestinal starch alpha-glucogenesis. *J Nutr* 2007;137:1725–33.

36. Nichols BL, Quezada-Calvillo R, Robayo-Torres CC, et al. Mucosal maltase-glucoamylase plays a crucial role in starch digestion and prandial glucose homeostasis of mice. *J Nutr* 2009;139:684–90.

37. Jones K, Sim L, Mohan S, et al. Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase. *Bioorg Med Chem* 2011;19:3929–34.

38. Eskandari R, Jones K, Rose DR, et al. Selectivity of 3'-O-methylponkoranol for inhibition of N- and C-terminal maltase glucoamylase and sucrase isomaltase, potential therapeutics for digestive disorders or their sequelae. *Bioorg Med Chem Lett* 2011;21:6491–4.

39. Sim L, Willemsma C, Mohan S, et al. Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N-terminal domains. *J Biol Chem* 2010;285:1763–70.

40. Sim L, Quezada-Calvillo R, Sterchi EE, et al. Human intestinal maltase-glucoamylase: crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity. *J Mol Biol* 2008;375:782–92.

41. Krasilnikoff PA, Gudman-Hoyer E, Moltke HH. Diagnostic value of disaccharide tolerance tests in children. *Acta Paediatr Scand* 1975; 64:693–8.

42. Perman JA, Barr RG, Watkins JB. Sucrose malabsorption in children: noninvasive diagnosis by interval breath hydrogen determination. *J Pediatr* 1978;93:17–22.

43. Douwes AC, Fernandes J, Jongbloed AA. Diagnostic value of sucrose tolerance test in children evaluated by breath hydrogen measurement. *Acta Paediatr Scand* 1980;69:79–82.

44. Lifschitz CH, Irving CS, Gopalakrishna GS, et al. Carbohydrate malabsorption in infants with diarrhea studied with the breath hydrogen test. *J Pediatr* 1983;102:371–5.

45. Davidson GP, Robb TA. Detection of primary and secondary sucrose malabsorption in children by means of the breath hydrogen technique. *Med J Aust* 1983;2:29–32.

46. Robayo-Torres CC, Opeku AR, Quezada-Calvillo R, et al. ¹³C-breath tests for sucrose digestion in congenital sucrase isomaltase-deficient and sacrosidase-supplemented patients. *J Pediatr Gastroenterol Nutr* 2009;48:412–8.

hydrolyze sucrose, maltose, short 1–4 linked glucose oligomers, branched (1–6 linked) α -limit dextrans, and starch (1). Exposure to these nutrients provokes osmotic diarrhea with pain, bloating, and abdominal distention; rapid small bowel transit and malabsorption of other nutrients; excessive bacterial fermentation of malabsorbed carbohydrate with colonic gas production and acidification of the stools; and at times, chronic malnutrition and failure to thrive (2). After the sucrase-isomaltase (SI) gene was identified on chromosome 3 (3q25–26) and was cloned in 1992 by Chantret and colleagues, more than 25 mutations in the gene responsible for the synthesis of SI have been discovered (3–6). These mutations result in a variety of defects in the folding of the synthesized propeptide chain; the initial high mannose and then complex glycosylation; the sequential export from the endoplasmic reticulum to the Golgi apparatus, and eventually to the apical membrane; the anchoring of the N-terminal aspect of the isomaltase subunit in the enterocyte microvillus membrane; and the normal architecture of the sucrase and isomaltase catalytic sites, which are independent of each other and can be affected separately, leading to isolated deficiencies (5,6). The intracellular phenotypic heterogeneity is reflected in a range of enzymatic capability ranging from completely absent sucrase activity to low but present residual activity and from completely absent isomaltase activity to normal activity. Because SI is responsible for approximately 60% to 80% of the maltase activity in the brush border of the enterocyte, maltase activity is also significantly reduced in almost all cases.

In addition to the degree of enzyme deficiency, the appearance of overt clinical manifestations of CSID is partially determined by the amount of sugar and starch being consumed. Approximately 60% of the total calories consumed in the average diet in the United States originate from carbohydrates, with 30% of carbohydrate calories deriving from sucrose (7). The typical adult consumes about 150 lb of sugar per year and 65 lb of sucrose. The influence of the dietary consumption of sucrose is best illustrated by the natural history of CSID in Greenland, where approximately 5% to 10% of Greenland Eskimos are affected (8). Before the introduction of a Western diet in the middle part of the last century provoked by the settlement of Greenland by northern Europeans from Denmark and other European countries, CSID was unknown among the indigenous population, who consumed a fish-and-marine mammal-based diet, relatively high in fat and protein and low in carbohydrates and sucrose. A marked increase in diarrhea and other gastrointestinal symptoms in the indigenous population led to studies in the 1970s that delineated the prevalence of CSID. The early introduction of sucrose and starch in the form of baby juices, baby food fruits and certain vegetables, and sucrose- and maltodextrin-containing infant formulas also plays a role in the timing of clinical manifestations of CSID.

Other hormonal and dietary factors and micronutrients also influence small intestinal sucrase activity. Unlike lactase activity

From the Established Products Division, Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey.

Address correspondence and reprint requests to Dr William R. Treem, Clinical Leader, Established Products Division, Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton-Harbourton Rd, Titusville, NJ 08560 (e-mail: wtreem@its.jnj.com).

W.R.T. received support from the Food and Drug Administration via an Orphan Drug Grant (FD-R-00854-01) for studies referred to in references 40 and 41, and from Quality of Life Medical Inc for studies summarized in reference 20. He is a paid consultant for Quality of Life Medical Inc.

The author reports no conflicts of interest.

Copyright © 2012 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

DOI: 10.1097/01.mpg.0000421401.57633.90

Clinical Aspects and Treatment of Congenital Sucrase-Isomaltase Deficiency

William R. Treem

Congenital sucrase-isomaltase deficiency (CSID) was first described by Weijers and colleagues in 1960 and has subsequently been defined as an inherited deficiency in the ability to

that is unresponsive to lactose consumption, sucrase activity is inducible by a high-sucrose, high-carbohydrate diet and reduced by a high-protein, low-carbohydrate diet (9). Both thyroxine and corticosteroids induce the expression of SI on the brush border of the enterocyte (10). In animal models, dietary-induced iron deficiency results in decreased small-bowel disaccharidase activity, with lactase affected more than SI (11). This appears to be the result of decreased gene expression caused by overexpression of PDX-1, a repressor of the lactase and sucrase promoter regions. PDX-1 overexpression can be reversed with restoration of a normal iron-containing diet and replenishment of iron stores. Naturally occurring phytochemicals in the diet (eg, cinnamon extract, onions, garlic, certain spices, mushrooms, chamomile tea) can act as inhibitors of amylase and intestinal α -glucosidases, thus influencing luminal sucrase activity (12). In patients with CSID and mutations allowing some residual SI activity, these hormonal and dietary factors may influence the onset and severity of symptoms.

PREVALENCE OF CSID

The actual prevalence of CSID is still a matter of debate. Substantial progress in cloning disease-causing mutations has opened the possibility of conducting large-scale population-based screening. In a recent study by Scott and colleagues, all 48 exons of the 100-kb SI gene on chromosome 3 were sequenced in 31 biopsy-proven patients with CSID and 55 different mutations were identified, with at least 1 of the 4 most common mutations found on 32 (59%) of the affected alleles (4). If one assumes the Hardy-Weinberg equilibrium for mutations in the population, then there is an 83% probability that an individual with severe clinical manifestations of CSID will have at least 1 of these 4 mutations. The results of this study raise the possibility in the near future of a genetic screening test both for population prevalence studies and to aid in the diagnosis of new cases. With the availability of DNA harvesting from buccal mucosa, the feasibility of genetic testing in young infants and children increases substantially. Studies are in progress to determine whether genetic testing also can be done on intestinal epithelial biopsy specimens opening the possibility of simultaneously determining disaccharidase levels and genetic mutations for CSID.

Clinical studies of relatively homogenous selected populations have yielded high rates of CSID, ranging from 5% to 10% in Greenland Eskimos, 3% to 7% in Canadian native peoples, and about 3% in Alaskans of native ancestry (13,14); however, estimates of the prevalence of CSID in other North American and European populations generally range from 1 in 500 to 1 in 2000 among non-Hispanic whites, with a lower prevalence in African Americans and whites of Hispanic descent. These studies evolved from older studies of intestinal disaccharidase levels in adult patients undergoing endoscopy for gastrointestinal symptoms (15,16). The estimates have shown low levels of sucrase activity >1 standard deviation (SD) below the mean in mucosal biopsy specimens from 2% to 9% of patients, even in the absence of overt mucosal injury. If one assumes that some of these patients represent heterozygotes for CSID, then the prevalence quoted above seems plausible; however, the diagnosis of CSID is rarely made even in infants and young children, suggesting the possibility that the phenotype of CSID may be much broader and more variable than previously thought and that a large proportion of affected adult and pediatric patients are not being tested and diagnosed.

This hypothesis receives support from the analysis of recently released whole exome sequence data (Exome Variant Server, <http://evs.gs.washington.edu/EVS>). Belmont and colleagues at the Children's Nutrition Research Center at the Baylor College of

Medicine reviewed the SI gene sequence data in a population of approximately 3500 North American white adults ascertained as controls or with atherosclerosis and no known bias for gastrointestinal disease. These data showed 271 rare missense variants with an aggregate allelic frequency of 0.03864. Based on this allele frequency, and assuming that the alleles segregate independently, Hardy-Weinberg proportions were used to estimate the frequency of homozygotes and compound heterozygotes for rare alleles. Although it is not known whether all of these variants result in decreased enzyme activity, the large number of variants could be consistent, with an estimated frequency of 1:670 affected patients and 7% carriers in this population (personal communication, Dr John Belmont, February 28, 2012; public data at the Exome Variant Server).

There are several pieces of clinical evidence that support the view that CSID is more prevalent than previously believed. Studies of disaccharidase levels from intestinal biopsy specimens sent to 2 pediatric reference laboratories have shown surprisingly frequent results for a pattern suggesting CSID. In 2 studies of almost 1000 biopsies each, sucrase deficiency was defined as >1 SD below the mean activity level in 1 study and $<10\%$ of the mean in another (17,18). As defined, sucrase deficiency was found in 11% and 13% of biopsy specimens in the 2 studies. Included were specimens with isolated sucrase or SI deficiency only (1.0% and 1.1%, respectively), SI and maltase-glucoamylase (MGAM) deficiency only (3.0% and 2.4%, respectively), and pandisaccharidase deficiency (5.8% in both studies). Pandisaccharidase deficiency was more likely accounted for by acquired diffuse intestinal villous injury. Although correlation with histology was not provided, the surprisingly high numbers of isolated SI and combined SI-MGAM deficiencies without lactase deficiency suggest that specific genetically determined enzyme deficiencies may be playing a role.

Although small intestinal disaccharidases are most often investigated in the clinical setting of diarrhea in infants and young children, the role of disaccharidase deficiencies and specifically SI deficiency in other gastrointestinal syndromes also has been entertained. Small series of patients with CSID have revealed a subgroup of adolescents and even adults who present with dyspepsia, gas, and /or irritable bowel syndrome (IBS) rather than the classic presentation of watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools in infancy (2,19,20). Karnsakul and colleagues studied 44 children and adolescents with dyspepsia, only 4 of whom had intermittent diarrhea (21). Patients underwent endoscopy with small bowel biopsies and disaccharidases and one-third had low sucrase activity (>1 SD from the mean), including 4 of 44 with isolated low sucrase activity, and 11 of 44 with sucrase and pandisaccharidase deficiency, but no significant villous atrophy. In addition, in preliminary follow-up studies of families with index cases of CSID uncovered in a child, parents with a long-term diagnosis of IBS were subsequently identified as having CSID (22).

After the sequencing of all of the exons of the CSID gene, most patients with CSID studied by Scott and colleagues have been found to be homozygous or compound heterozygotes for disease-causing mutations (4). Kerry and Townley showed that the parents of 4 children with CSID had intestinal sucrase activity below the lower limits of normal and a sucrase:lactase ratio <0.8 , both consistent with the heterozygous state and supporting an autosomal recessive pattern of inheritance (23); however, 3 patients in Scott and colleagues' study who presented with classical symptoms and biopsy-proven absent sucrase activity with absent or low isomaltase activity, and 2 others with milder decreases in both enzymes, appeared to be heterozygote carriers with a mutation on 1 allele and a wild-type gene on the other. These small studies lend credence to the hypothesis that CSID is more prevalent than previously

thought; manifests with milder phenotypes that may even omit diarrhea as a prominent symptom; and may be transmitted in ways other than strict autosomal recessive inheritance. The combination of the “heterozygous” state with other genetic and/or dietary and nutritional interactions may provoke gastrointestinal symptoms in certain patients.

PRESENTATION AND NATURAL HISTORY OF CSID

The classical presentation of CSID is severe watery diarrhea, failure to gain weight, irritability, and diaper rash in a 9- to 18-month-old infant who has been exposed to sucrose and starch in the form of baby juices, baby food fruits, teething biscuits, crackers, and other starches. Factors that contribute to the predilection for a presentation during infancy include the shorter length of the colon and a decreased capacity for colonic reabsorption of fluid and electrolytes, more rapid small intestinal transit, a high carbohydrate diet, and the ontogeny of amylase activity that does not reach “adult” levels until the second year of life (24); however, clinical studies during the last 20 years and a retrospective review of 65 patients with CSID have revealed a variety of presentations that defy the conventional view (5,22,25,26). Table 1 describes the symptoms at presentation in these 65 patients. Although most have presented with the classic symptoms, a significant minority have only been diagnosed between 2 to 8 years old after normal growth and a previous diagnosis of chronic nonspecific diarrhea of childhood (“toddler’s diarrhea”), or even later during adolescence or young adulthood carrying a diagnosis of diarrhea-predominant IBS. Up to one-third have had vomiting as a prominent symptom, suggesting again that dyspepsia, gas, bloating, and even reflux-like symptoms may predominate in some patients. Other anecdotal reports have mentioned hypercalcemia and nephrocalcinosis in infants with CSID, and even renal calculi in 2 adults with CSID (27,28).

In a follow-up study of 65 patients with CSID who responded to a questionnaire after being identified by a record of prescriptions for enzyme replacement therapy, 53 of 65 reported the onset of symptoms before 1 year of age, 7 between 1 and 10 years old, and 5 after 10 years of age (22); however, the age at which a diagnosis was made was shifted to the right, with only 17 of 65 diagnosed in the first year, 30 between 1 and 5 years, 10 between 5 and 10 years, and 8 after 10 years of age. The potential reasons for this delay in diagnosis include a mistaken diagnosis of protein intolerance in infancy with multiple formula changes and the elimination of glucose oligomers (maltodextrin) that are partially hydrolyzed by sucrase in favor of glucose monomers in amino acid–based formulas (29). A diagnosis of food allergy often also leads to the elimination juices and baby foods that may have a high sucrose load, further masking the true underlying cause of diarrhea in patients with CSID. Later in childhood, a diagnosis of chronic

nonspecific diarrhea often will result in a lower carbohydrate, higher fat diet, and the elimination of all juices with improvement in symptoms of patients with CSID (30). Older children and adolescents with CSID and diarrhea-predominant IBS may learn which foods trigger their symptoms and avoid those foods, thus masking their true diagnosis. In addition, chronic carbohydrate malabsorption may act as a prebiotic stimulus to colonic bacterial growth, creating a significant increase in the capacity to ferment and salvage malabsorbed carbohydrate, and stimulate colonic short-chain fatty acid synthesis and sodium and fluid reabsorption by the colonocyte (31). Colonic bacterial flora “adaptation” may thus contribute to a decrease in diarrhea symptoms over time in some patients with CSID.

DIAGNOSIS OF CSID

At present, the gold standard for the diagnosis of CSID remains small intestinal biopsy specimens assayed for lactase, sucrase, isomaltase (palatinase), and maltase activity. In general, the criteria applied to make the diagnosis of CSID include normal small bowel morphology in the presence of absent or markedly reduced sucrase activity, isomaltase activity varying from 0 to full activity, reduced maltase activity, and normal lactase activity, or in the setting of reduced lactase, a sucrase:lactase ratio of <1.0. Table 2 summarizes the disaccharidase activities in 36 patients with CSID; all were included in 2 pivotal clinical trials included as part of the new drug application (NDA) for sacrosidase submitted to the Food and Drug Administration (FDA; NDA 20-772/S-011, 1998). Sucrase activity was absent in 24 of 36 (66%) patients, and in all but 3, activity was less than the third percentile of 977 values in “controls,” which consisted of unselected small bowel biopsies from children with diarrhea and other gastrointestinal symptoms (18). All sucrase activity values in patients with CSID were <10th percentile of controls. Almost two-thirds (23/35) had absent palatinase (isomaltase) activity, and all but 2 were <10th percentile, with 1 of those in the normal range and 1 with elevated activity. Maltase activity was variable. No patient had absent activity, but the mean equaled 41.5 U/g protein and the majority (25/36, 69%) exhibited reductions >2 standard deviations from the mean in controls. All but 2 patients demonstrated <10% of control activity. Two patients exhibited normal activity. There was no clear correlation between absent or residual sucrase activity with the spectrum of decreased maltase activity. Because the brush border enzyme MGAM is responsible for at least 20% of maltase activity, those patients with low maltase activity may be examples of combined deficiencies of SI and MGAM (32,33). Elevated lactase enzyme activity levels were found in 3 of our patients and have been found in a small minority of patients with CSID in most studies to date.

Recent studies of the SI gene in symptomatic patients with intestinal disaccharidase deficiency have identified compound

TABLE 1. Presenting symptoms in 65 patients with CSID (22)

Symptom	No. patients (%)
Diarrhea	62 (95)
Bloating/gas	55 (85)
Abdominal pain	43 (66)
Irritability	43 (66)
Diaper rash	40 (62)
Failure to thrive	39 (60)
Nausea/vomiting	22 (34)
Irritable bowel syndrome	12 (18)

TABLE 2. Intestinal biopsy disaccharidase activities in 36 patients with CSID (U/g protein) (42,43)

	Sucrase (n = 36)	Isomaltase (palatinase) (n = 35)	Maltase (n = 36)	Lactase (n = 36)
Mean	2.3	1.9	41.5	30.5
Standard deviation	4.4	5.8	34.7	19.2
Median	0	0	29.2	27.6
Minimum	0	0	10.9	5.2
Maximum	15.4	33.3	166.7	101.5

heterozygotes with less severely reduced sucrase and isomaltase and even what appears to be true heterozygotes with 1 normal allele and what appears to be a more severe mutation on the other allele (4–6,34). One patient in the cohort studies by Scott et al appeared to have normal wild-type genes on both alleles with moderately reduced sucrase activity and symptoms provoked by sucrose consumption, which suggested acquired sucrase deficiency even in the presence of normal small intestinal morphology (4). Other causes of false-positive results come from biopsies taken in the proximal duodenum, where disaccharidase levels are often only approximately two-thirds of the levels found in the proximal jejunum (35). In addition, mishandling of biopsy specimens resulting in inadequate rapidity of freezing and premature thawing can result in a diffuse reduction in disaccharidase activity. Studies of replicate intestinal biopsy disaccharidase assays have demonstrated a coefficient of variation of 27%, stressing the variability of the assay (18). This variation emphasizes the role of clinical judgment in making the diagnosis of CSID from mucosal disaccharidase assay values.

Other less invasive methods of diagnosis include the sucrose breath hydrogen study and differential urinary disaccharides (36,37). Although relatively easy to accomplish, the sucrose breath hydrogen study is compromised by significant contamination from both false-positives (secondary sucrase deficiency from villous injury, dumping syndrome, and bacterial overgrowth) and false-negatives (nonhydrogen producers, antibiotic interference, delayed gastric emptying). Also, this test can provoke severe symptoms as a result of the 2-g/kg oral sucrose load given to patients with CSID. The differential urinary disaccharide test examines the ratio of urinary sucrose:lactulose, which should approach 1.0 in patients with CSID; however for accurate results, this test relies on obtaining an accurate 10-hour urine collection that is difficult in many infants and young children and the presence of normal intestinal permeability.

Figure 1 summarizes data from studies of the utility of a ^{13}C -sucrose breath test to diagnose CSID (38). This test requires the administration of a small dose of uniformly labeled ^{13}C -sucrose mixed in unlabeled maltodextrin in water as a carrier and the subsequent collection of $^{13}\text{CO}_2$ -enriched breath samples every 15 minutes for 2 hours. The separate administration of ^{13}C -glucose mixed in maltodextrin and collection of $^{13}\text{CO}_2$ allows ^{13}C -sucrose hydrolysis and digestion to be expressed as a coefficient of glucose oxidation (CGO). As Figure 1 shows, the mean percent CGO of ^{13}C -sucrose in 10 patients with CSID is $25\% \pm 21\%$ compared with $146\% \pm 45\%$ in 10 age-matched controls. A cutoff of 79% CGO yields 100% sensitivity and specificity for CSID. Although the test

requires 2 breath tests and infrared spectrophotometry, it has several advantages: it is noninvasive, has excellent sensitivity and specificity, and avoids provocation of gastrointestinal symptoms because of an excessive sucrose load.

TREATMENT OF CSID

Previous follow-up studies of children with CSID treated with sucrose- and starch-restricted diets have demonstrated that only 10% of patients remain consistently asymptomatic, and 60% to 75% still experience diarrhea, gas, and/or abdominal pain, with a lower proportion (20%) complaining of nausea. Only approximately half of these children are compliant with the prescribed diet (39,40). Harms and colleagues described the amelioration of both hydrogen production and gastrointestinal symptoms in 8 children with CSID treated with Baker's yeast (*Saccharomyces cerevisiae*) cakes before a sucrose breath hydrogen test (41). *S. cerevisiae* contains a β -fructofuranoside fructohydrolase with sucrase but not maltase or isomaltase activity. By using specific growing conditions to promote increased enzyme activity and belt drying to preserve this activity, the food industry has for many years been using this enzyme to convert sugarcane (sucrose) to molasses and keep the centers of cream-filled candies liquid. Preclinical studies on a liquid preparation derived from the *S. cerevisiae* (sacrosidase) grown under these conditions showed that 1 mL of this preparation contained approximately 8500 U of sucrose-hydrolyzing activity (8500 μmol glucose formed per minute per milliliter) (42). Sacrosidase was free of lactase, isomaltase, or maltase activity; rich in mannose glycosylation; maintained stable activity with refrigeration; and did not lose significant activity with a pH down to 1.0. Incubation of the enzyme with pepsin at or near the pH optimal for pepsin activity (1.5), however, produced a rapid loss of activity. Preincubation of the pepsin with bovine serum albumin provided a decoy for the pepsin and allowed preservation of sacrosidase activity even at a pH of 1.5.

Figure 2 shows the results of sucrose breath hydrogen studies on the first child with CSID treated with sacrosidase under an orphan drug grant from the FDA. Two breath tests with 2 and 4 g/kg sucrose loads produced a marked rise in breath hydrogen and gastrointestinal symptoms; however, breath tests accompanied by sacrosidase treatment prevented the rise in breath hydrogen and the symptoms. Subsequent pivotal trials in >40 subjects between the ages of 5 months and 29 years were conducted, with the diagnosis of CSID based on chronic watery diarrhea with an acid pH, a tissue




FIGURE 1. Data summary from studies of the utility of a ^{13}C -sucrose breath test to diagnose CSID.




FIGURE 2. Results of sucrose breath hydrogen studies on the first child with CSID treated with sacrosidase under an orphan drug grant from the Food and Drug Administration.

sucrase activity level of <10% of the mean of controls, a normal lactase level, and a normal lactose breath hydrogen test (42,43). These multicenter, double-blind, randomized studies used 3 increasing dilutions of sacrosidase and an undiluted form in 4 arms given to each subject in random order during a 10-day period in which time the subjects consumed a normal sucrose-containing (approximately $1.75\text{--}2.5\text{ g} \cdot \text{kg}^{-1} \cdot \text{day}^{-1}$) and starch-containing ($5.2\text{--}5.8\text{ g} \cdot \text{kg}^{-1} \cdot \text{day}^{-1}$) diet. Two breath hydrogen studies (with and without sacrosidase) were performed in the first study and 3 (with and without sacrosidase and with sacrosidase plus cow's milk acting as a pepsin decoy) in the second pivotal study.

The results of these studies can be summarized as follows. All dilutions of sacrosidase reduced symptoms of sucrose

malabsorption provoked by both the breath tests and the period of unrestricted diet; the undiluted preparation most significantly reduced watery stools, gas, cramps, and bloating. Full-strength (undiluted) sacrosidase normalized these symptoms and the stool frequency in comparison with the baseline period of a sucrose-free, starch-restricted diet and no sacrosidase treatment. Full-strength sacrosidase resulted in 81% of patients, consuming an unrestricted diet, remaining asymptomatic, compared with 78% untreated during the baseline, diet-restricted period. Excessive breath hydrogen production was blocked by the double-blind administration of sacrosidase compared with placebo and was further reduced by consuming milk before sucrose ingestion (Fig. 3A). A study of the ^{13}C -sucrose breath test with and without sacrosidase administration




FIGURE 3. A, Excessive breath hydrogen production blocked by the double-blind administration of sacrosidase compared with placebo and was further reduced by consuming milk before sucrose ingestion. B, A study of the ^{13}C -sucrose breath test with and without sacrosidase administration confirmed these results and shows that all of the subjects had normalized CGO with therapy.

TABLE 3. Persistence of symptoms in 65 patients with CSID treated with Sucraida (22)

Symptom frequency	Diarrhea, %	Bloating/gas, %	Nausea/vomiting, %	Abdominal pain, %
0 times per week	46	43	96	91
1 time per week	28	18	4	9
2–3 times per week	12	13	0	0
>3 times per week	14	26	0	0

confirmed these results and shows that all of the subjects had normalized CGO with therapy (Fig. 3B) (37). Adverse events were limited to unrelated episodes of vomiting, pallor, and dehydration, each in a single subject, and a possibly related event of wheezing in a young child with known asthma, who was later found to have a positive skin test for sacrosidase (43). This incident led to the recommendation on the label to perform skin tests on patients with asthma before sacrosidase is administered. No other patients have been described with this adverse effect. These studies resulted in the submission of an NDA to the FDA and approval of Sucraida (sacrosidase) as treatment for CSID in 1998. Treatment was covered by Medicaid, after which private insurance coverage was approved. Recommendations for dosing on the label suggest using 1 mL with meals or snacks for patients <15 kg and 2 mL with meals or snacks for those >15 kg. Doses are to be split, with half the dose given at the onset of a meal and the other half midway through, when the intragastric environment is buffered to a higher pH and pepsin may be partially decoyed by other proteins.

A preliminary postmarketing surveillance study was conducted involving 229 patients with CSID who received prescriptions for Sucraida (sacrosidase) between 2004 and 2009. Results are summarized in a published abstract and in the proceedings of this symposium (22). Sixty-nine of 229 questionnaires were returned from 60 of 69 patients in 27 states in the United States and from 9 patients in 4 other countries. Included were 39 male patients and 66 of 69 patients younger than 18 years old. Sixty-five patients continued taking Sucraida; 2 had abandoned it because of lack of efficacy and 2 because of its cost. The median duration of therapy was 3 years and one-third had been treated continuously for >5 years. Nine of 65 (14%) patients were exceeding the maximum recommended dose per meal (2 mL) to try to control symptoms. Either a normal diet or a mild sucrose- and starch-restricted diet was consumed by 41 of 65 (65%) patients, but in 27%, strict sucrose restriction with either mild or strict starch restriction was necessary to maintain acceptable suppression of symptoms, even while taking Sucraida. Table 3 summarizes symptoms while patients are being treated with Sucraida. The majority (59/65, 92%) had <3 bowel movements per day, and 74% experienced either no diarrhea or diarrhea once per week, 12% had diarrhea 2 to 3 times per week, and 14% had diarrhea >3 times per week. In 74%, bloating occurred <3 times per week. Abdominal pain and nausea/vomiting were not seen in any patients >1 time per week and were completely absent in >90% of patients. The most common adverse events reported included constipation in 6 of 65, headaches in 5 of 65, and sleep disturbances in 8 of 65. None of these events resulted in discontinuing Sucraida.

CONCLUSIONS

Both clinical studies and molecular/genetic investigations suggest that CSID is a more common disease than previously believed and that genetically modified small intestinal SI digestion accounts for a broad spectrum of clinical phenotypes, including some potentially hidden in large cohorts of patients with IBS, chronic nonspecific diarrhea, and perhaps even dyspepsia (44).

The advent of noninvasive breath tests with excellent sensitivity and specificity and genetic tests of relatively common mutations in the CSID gene hold out the promise of more accurate population prevalence studies and diagnosis of less classic cases, even in adults who are believed to have lifelong functional bowel disorders. The recent approval of an enzyme replacement therapy has allowed liberalization of the previously mandatory sucrose restrictive diet and restored a more normal lifestyle, particularly to infants and young children exposed to a high carbohydrate diet (45). Further modifications of this therapy with the possible additions of enzymes geared to supplement higher maltase and glycoamylase activity may be in the offing to help patients cope with the continued problem of starch malabsorption. Research has demonstrated that additional amylase activity amplifies the effect of SI and MGAM on starch digestion and offers another potential addition to enzyme replacement therapy (18,46).

REFERENCES

1. Weijers H, Va De Kamer J, Mossel D, et al. Diarrhoea caused by deficiency of sugar-splitting enzymes. *Lancet* 1960;6:296–7.
2. Treem W. Congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr* 1995;21:1–14.
3. Chantret I, Lacasa M, Chevalier G, et al. Sequence of the complete cDNA and the 5' structure of the human sucrase-isomaltase gene. Possible homology with a yeast glucoamylase. *Biochem J* 1992;285: 915–23.
4. Uhrich S, Wu Z, Huang J, et al. Four mutations in the SI gene are responsible for the majority of clinical symptoms of CSID. *J Pediatr Gastroenterol Nutr* 2012;55(Suppl 2):S34–5.
5. Alfalah M, Keiser M, Leeb T, et al. Compound heterozygous mutations affect protein folding and function in patients with congenital sucrase-isomaltase deficiency. *Gastroenterology* 2009;136:88–92.
6. Naim HY, Heine M, Zimmer KP, et al. Congenital sucrase-isomaltase deficiency: heterogeneity of inheritance, trafficking, and function of an intestinal enzyme complex. *J Pediatr Gastroenterol Nutr* 2012;55 (Suppl 2):000–000.
7. Codain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. *Am J Clin Nutr* 2005;81:341–54.
8. Gudmand-Hoyer E, Fenger H, Kern-Hansen P, et al. Sucrase deficiency in Greenland. *Scand J Gastroenterol* 1987;22:24–8.
9. Goda T, Koldovsky O. Dietary regulation of small intestinal disaccharidases. *World Rev Nutr Diet* 1988;57:275–329.
10. Yeh KY, Yeh M, Holt PR. Differential effects of thyroxine and cortisone on jejunal sucrase expression in suckling rats. *Am J Physiol* 1989; 256:604–12.
11. West A, Oates P. Decreased sucrase and lactase activity in iron deficiency is accompanied by reduced gene expression and upregulation of the transcriptional repressor PDX-1. *Am J Physiol Gastrointest Liver Physiol* 2005;289:G1108–14.
12. Tundis R, Loizzo R, Menichini F. Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. *Mini Rev Med Chem* 2010;10:315–31.
13. Bell R, Draper H, Bergan JG. Sucrose, lactose, and glucose intolerance in northern Alaskan Eskimos. *Am J Clin Nutr* 1973;26:1185–90.

14. Ellestad-Sayad J, Haworth J, Hildes J. Disaccharide malabsorption and dietary patterns in two Canadian Eskimo communities. *Am J Clin Nutr* 1978;31:1473–8.
15. Peterson M, Herber R. Intestinal sucrase deficiency. *Trans Assoc Am Physicians* 1967;80:275–83.
16. Welsh J, Poley J, Bhatia M, et al. Intestinal disaccharidase activities in relation to age, race, and mucosal damage. *Gastroenterology* 1978;75:847–55.
17. Gupta S, Chong S, Fitzgerald J. Disaccharidase activities in children: normal values and comparison based on symptoms and histological changes. *J Pediatr Gastroenterol Nutr* 1999;28:246–51.
18. Quezada-Calvillo R, Robayo-Torres C, Ao Z, et al. Luminal substrate “brake” on mucosal maltase-glucoamylase activity regulates total rate of starch digestion to glucose. *J Pediatr Gastroenterol Nutr* 2007; 45:32–43.
19. Muldoon C, Maguire P, Gleeson F. Onset of sucrase-isomaltase deficiency in late adulthood. *Am J Gastroenterol* 1999;94:2298–9.
20. Ringrose R, Preiser H, Welsh J. Sucrase-isomaltase (palatinase) deficiency diagnosed during adulthood. *Dig Dis Sci* 1980;25:384–7.
21. Karnsakul W, Luginbuel H, Hahn D, et al. Disaccharidase activities in dyspeptic children: biochemical and molecular investigations of maltase-glucoamylase activity. *J Pediatr Gastroenterol Nutr* 2002;35:551–6.
22. Treem WR, Douglas M, Duong S, et al. Congenital sucrase-isomaltase deficiency (CSID) in the era of Sucraid. *J Pediatr Gastroenterol Nutr* 2009;53(Suppl 1):E85.
23. Kerry K, Townley R. Genetic aspects of intestinal sucrase-isomaltase deficiency. *Aust Paediatr J* 1965;1:223–35.
24. Auricchio S, Ciccimarra F, Moauro L, et al. Intraluminal and mucosal starch digestion in congenital deficiency of intestinal sucrase and isomaltase activities. *Pediatr Res* 1972;6:832–9.
25. Baudon J, Veinberg F, Thiolouse E, et al. Sucrase-isomaltase deficiency: changing pattern over two decades. *J Pediatr Gastroenterol Nutr* 1996;22:284–8.
26. Treem WR. Clinical heterogeneity in congenital sucrase-isomaltase deficiency. *J Pediatr* 1996;128:727–9.
27. Belmont J, Reid B, Taylor W, et al. Congenital sucrase-isomaltase deficiency presenting with failure to thrive, hypercalcemia, and nephrocalcinosis. *BMC Pediatr* 2002;2:1–7.
28. Starnes C, Welsh JD. Intestinal sucrase-isomaltase deficiency and renal calculi. *N Engl J Med* 1970;282:1023–4.
29. Newton T, Murphy M, Booth IW. Glucose polymer as a cause of protracted diarrhea in infants with unsuspected congenital sucrase-isomaltase deficiency. *J Pediatr* 1996;128:753–6.
30. Treem WR. Chronic non-specific diarrhea of childhood. *Clin Pediatr* 1992;31:413–20.
31. Treem WR, Ahsan N, Kastoff G, et al. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in-vitro studies of carbohydrate fermentation. *J Pediatr Gastroenterol Nutr* 1996;23:280–6.
32. Skovbjerg H, Krasilnikoff P. Maltase-glucoamylase and residual isomaltase in sucrose-intolerant patients. *J Pediatr Gastroenterol Nutr* 1986;5:365–71.
33. Lebenthal E, U KM, Zheng BY, et al. Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children. *J Pediatr* 1994;124:541–6.
34. Sander P, Alfalah M, Keiser M, et al. Novel mutations in the human sucrase-isomaltase gene (SI) that cause congenital carbohydrate malabsorption. *Hum Mutat* 2006;27:119.
35. Smith J, Mayberry J, Ansell ID, et al. Small bowel biopsy for disaccharidase levels: evidence that endoscopic forceps biopsy can replace the Crosby capsule. *Clin Cim Acta* 1989;183:317–21.
36. Perman J, Barr R, Watkins JB. Sucrose malabsorption in children: noninvasive diagnosis by interval breath hydrogen determination. *Pediatrics* 1978;93:17–22.
37. Bjarnason I, Batt R, Catt S, et al. Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity cause by (-glucosidase inhibition, primary hypolactasia, and celiac disease. *Gut* 1996;39:374–81.
38. Robayo-Torres C, Opekun A, Quezada-Calvillo R, et al. 13C-breath tests for sucrose digestion in congenital sucrase isomaltase-deficient and sacrosidase-supplemented patients. *J Pediatr Gastroenterol Nutr* 2009;48:412–8.
39. Antonowicz I, Lloyd-Still J, Khaw KT, et al. Congenital sucrase-isomaltase deficiency. Observations over a period of 6 years. *Pediatrics* 1972;49:847–53.
40. Kilby A, Burgess E, Wigglesworth S, et al. Sucrase-isomaltase deficiency. A follow-up report. *Arch Dis Child* 1978;53:677–9.
41. Harms H, Bertele-Harms R, Bruer-Kleis D. Enzyme-substitution therapy with the yeast *Saccharomyces cerevisiae* in congenital sucrase-isomaltase deficiency. *N Engl J Med* 1987;316:1306–9.
42. Treem WR, Ahsan N, Sullivan B, et al. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. *Gastroenterology* 1993;105:1061–8.
43. Treem WR, McAdams L, Stanford L, et al. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr* 1999;28:137–42.
44. Rahhal R, Bishop W. Sacrosidase trial in chronic non-specific diarrhea in children. *Open Pediatr Med J* 2008;2:35–8.
45. Lucke T, Keiser M, Illsinger S, et al. Congenital and putatively acquired forms of sucrase-isomaltase deficiency in infancy: effects of sacrosidase therapy. *J Pediatr Gastroenterol Nutr* 2009;49:485–7.
46. Liakopoulou-Kyriakides M, Karakatsanis A, Stamatoudis M, et al. Synergistic hydrolysis of crude corn starch by α -amylases and glucoamylases of various origins. *Cereal Chem* 2001;78:603–7.

Congenital Sucrase-Isomaltase Deficiency: Heterogeneity of Inheritance, Trafficking, and Function of an Intestinal Enzyme Complex

*Hassan Y. Naim, *Martin Heine, and [†]Klaus-Peter Zimmer

Brush border membranes are the largest exposed surfaces in tissues. They constitute the interface between the “milieu extérieur” and the “milieu interieur” of the body in a variety of organs such as the gastrointestinal tract and bile canaliculi, where hydrolytic, absorptive, and secretory processes take place. The intestinal mucosa is the exclusive site for nutrient metabolism and subsequent uptake of the generated products, such as monosaccharides and amino acids. The hydrolysis and absorption of micronutrients are achieved by the concerted action of hydrolases and transporters that are predominantly located in the brush border membranes (BBMs) (1).

The hydrolases are divided into 2 major families, the peptidases and the disaccharidases (2). The peptidases, such as aminopeptidases N (CD13), A, and W, carboxypeptidases P and M, dipeptidylpeptidase IV, or α -glutamyl transpeptidase, are expressed in many tissues, including the intestine and the kidney (3,4). The

From the *Department of Physiological Chemistry, University of Veterinary Medicine Hannover, Hannover, and the [†]Pediatric Clinic and Polyclinic, University of Giessen, Giessen, Germany.

Address correspondence and reprint requests to Hassan Y. Naim, PhD, Department of Physiological Chemistry, University of Veterinary Medicine Hannover, Bünteweg 17, D-30559 Hannover, Germany (e-mail: hassan.naim@tih-hannover.de).

The work was supported by SFB 280 and SFB 621 from the Deutsche Forschungsgemeinschaft (DFG, Bonn, Germany) to H.Y.N.

The authors report no conflicts of interest.

Copyright © 2012 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

DOI: 10.1097/01.mpg.0000421402.57633.4b



NIH Public Access

Author Manuscript

J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2014 March 17.

Published in final edited form as:

J Pediatr Gastroenterol Nutr. 2009 April ; 48(4): 412–418.

¹³C-Breath Tests for Sucrose Digestion in Congenital Sucrase Isomaltase Deficient and Sacrosidase Supplemented Patients

Claudia C. Robayo-Torres, MD,

USDA/ARS Children's Nutrition Research Center, Departments of Pediatrics-Nutrition, Baylor College of Medicine, Houston, TX crobayo@bcm.edu

Antone R. Opekun, PA-C,

Departments of Pediatrics and Medicine, Baylor College of Medicine, Houston, TX aopekun@bcm.edu

Roberto Quezada-Calvillo, PhD,

Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí (UASLP), San Luis Potosí, Mexico rqc@uaslp.mx

Villa Xavier, MD,

Department of Pediatric Gastroenterology, Hepatology and Nutrition, University of Texas Medical Branch. Galveston, TX. xavilla@utmb.edu

E. O'Brian Smith, Ph.D,

USDA/ARS Children's Nutrition Research Center, Department of Pediatrics-Nutrition, Baylor College of Medicine, Houston, TX esmith@bcm.tmc.edu

Marilyn Navarrete, MA,

USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX rilynn@bcm.tmc.edu

S. Susan Baker, MD, and

Department of Pediatric Gastroenterology, State University NY at Buffalo, Buffalo, NY. sbaker@upa.chob.edu

Buford L Nichols, MD, MS

USDA/ARS Children's Nutrition Research Center, Department of Pediatrics-Nutrition, Baylor College of Medicine, Houston, TX

Abstract

Congenital sucrase-isomaltase deficiency (CSID) is characterized by absence or deficiency of the mucosal sucrase-isomaltase enzyme. Specific diagnosis requires upper gastrointestinal biopsy with evidence of low to absent sucrase enzyme activity and normal histology. The hydrogen breath test (BT) is useful but is not specific for confirmation of CSID. We investigated a more specific ¹³C-sucrose labeled BT.

Objectives—were to determine if CSID can be detected with the ¹³C-sucrose BT without duodenal biopsy sucrase assay and if the ¹³C-sucrose BT can document restoration of sucrose digestion by CSID patients after oral supplementation with sacrosidase (Sucraid®).

Methods—Ten CSID patients were diagnosed by low biopsy sucrase activity. Ten controls were children who underwent endoscopy and biopsy because of dyspepsia or chronic diarrhea with

Correspondence to: Buford L. Nichols, USDA/ARS Children's Nutrition Research Center, Department of Pediatrics-Nutrition, Baylor College of Medicine, 1100 Bates Street, Houston, TX 77030, bnichols@bcm.edu, Telephone number: 713 798 7018, Fax number: 713 798 7057.

normal mucosal enzymes activity and histology. Uniformly-labeled ^{13}C -glucose and ^{13}C -sucrose loads were orally administered. $^{13}\text{CO}_2$ breath enrichments were assayed using an infrared spectrophotometer. In CSID patients the ^{13}C -sucrose load was repeated adding Sucraid®. Sucrose digestion and oxidation were calculated as a mean % coefficient of glucose oxidation (% CGO) averaged between 30 and 90 minutes.

Results—Classification of patients by ^{13}C -sucrose BT % CGO agreed with biopsy sucrase activity. The breath test also documented the return to normal of sucrose digestion and oxidation after supplementation of CSID patients with Sucraid®.

Conclusion— ^{13}C -sucrose BT is an accurate and specific non-invasive confirmatory test for CSID and for enzyme replacement management.

Keywords

^{13}C -breath test; glucose oxidation; congenital sucrase-isomaltase deficiency; sucrose digestion; sacrosidase supplementation

INTRODUCTION

Sucrose, also known as table sugar, is a disaccharide formed by glucose and fructose monosaccharide units. Sucrose is present in the human diet in fruits and is added to many prepared foods as refined beet or cane table sugar. Sucrase is the only brush border enzyme that digests sucrose. The membrane bound complex sucrase-isomaltase (SI) hydrolyzes disaccharide sucrose to free monosaccharides that are transported from the lumen by SGLT-1, GLUT-2, and GLUT-5 (2). A percentage of the absorbed glucose and fructose is quickly oxidized and exhaled as CO_2 and the remainder is metabolized or stored. SI has two maltase activities, which together with the two maltase activities of the maltase-glucoamylase (MGAM) complex, digest starch to free glucose. These four activities are better described as α -glucosidases. Approximately 60 to 80% of all mucosal α -glucosidase activity is accounted for by SI and the remainder of activity is due to MGAM (1). SI also has isomaltase and palatinase activities associated with the membrane bound isomaltase (I) portion of the enzyme complex.

Congenital sucrase-isomaltase deficiency (CSID) is an autosomal recessive intestinal disease caused by mutations of the SI gene (3–6). Duodenal mucosal histology is always normal. CSID patients have different phenotypes of enzymatic activities associated to SI, ranging from reductions of sucrase activity to total absence, as well as variable absence of isomaltase activity (7–10). Low sucrase activity leads to malabsorption of sucrose, resulting in dyspeptic-like symptoms such as diet-related chronic osmotic diarrhea and abdominal pain. Only rarely does CSID lead to failure to thrive (12). The severity of symptoms is related to the amount of sucrase activity and quantity of sucrose fed (11,12). A reduced maltase activity is expected to occur in patients with CSID because both subunits in the SI complex contribute to the total mucosal maltase activity (1). The low maltase activity can lead to malabsorption of starch products which may contribute to symptoms of dyspepsia and chronic abdominal pain (13). The prevalence of biopsy-assay proven CSID is 0.02% in individuals of European descent but is reported as high as 10% in indigenous Greenlanders (14). Frequency of heterozygous individuals carrying the CSID gene who have low but not deficient sucrase activity and normal small intestinal histology is reported to be from 2 to 9% in European Americans (7, 12). We found a frequency of isolated sucrase deficiency of 1% in our recent study of unselected clinically indicated duodenal biopsy enzyme assays (1).

Specific diagnosis of CSID presently requires duodenal biopsies with low to absent sucrase activity detected by enzyme assay and presence of normal histology to rule out secondary

deficiency. (12, 13, 15). Multiple genotypes make it impossible to establish a single molecular test suitable for the diagnosis of all CSID (7). The technique for diagnosis of SI deficiency by intestinal biopsy and assay of mucosal hydrolysis of sucrose was first described forty years ago by Charlotte M. Anderson et. al. (16). Presently the principles for diagnosis of SI deficiencies remain the same but the development of less invasive and less complex techniques is needed. The simplest treatment for CSID is dietary sucrose and occasionally starch restriction. Enzyme supplementation with liquid yeast sacrosidase (sucrase) enzyme derived from *Saccharomyces cerevisiae* relieves clinical symptoms and sucrose malabsorption in CSID patients. (17, 18, 19).

A hydrogen breath test (H_2 BT) for detecting carbohydrate malabsorption was introduced in the early 1970's creating the first clinical application for assessment of lactose malabsorption. The noninvasive nature of H_2 BT makes it particularly useful for application in pediatric clinical practice as an indirect test of carbohydrate malabsorption but it is not specific for the diagnosis of CSID (20). False-negative results may be obtained because of many factors affecting the H_2 production. The test requires absence of small bowel bacterial overgrowth and presence of colonic bacterial flora capable of fermenting proximally malabsorbed carbohydrate. There is great variability of fermentation by the colonic flora and no quantification of proximal carbohydrate malabsorption is possible. Failure to detect H_2 occurs in 2 to 40% of subjects. (21) A clinical problem arising from the H_2 BT is the large load of sucrose given to the patient. In CSID patients this load often precipitates severe symptoms of sucrose intolerance.

An evolution of the H_2 BT introduced in the early 1970's was the measurement of isotope-labeled CO_2 in breath using ^{13}C or ^{14}C (22). These tests depend on measurement of changes in isotope labeled breath CO_2 concentration; delta over baseline (ΔOB), detected by mass spectrometry or nuclear magnetic resonance (NMR) (23, 24). Isotope ratio ($^{13}C/^{12}C$) enrichment measured by mass spectrometry is the traditional method for BT and has high accuracy for low levels of enrichment (0.001 to 0.01 percent) (25–27). Most recently infrared mass-dispersion spectrophotometry has been introduced for breath $^{13}C/^{12}C$ isotope measurements and is clinically useful due to its simplicity and short turnaround time (28–30). Since the introduction of mass spectrometers for the detection of the stable isotope of ^{13}C in expired air the BT technique has been adapted for the study of malabsorption in the pediatric population with collection systems that are well-tolerated by infants and toddlers who can not actively cooperate (32, 33). The instruments required for measurement of ^{13}C -labeled CO_2 ($^{13}CO_2$) are less expensive now and naturally enriched and purified stable isotope labeled substrates are currently available (34, 35). The substrates most commonly used for $^{13}C/^{12}C$ BT include ^{13}C -labeled carbohydrates, starch, fatty acids, bile acids, amino acids and urea. Clinical applications include evaluation of the mucosal function, bacterial overgrowth, gastrointestinal motility, carbohydrate absorption, bile acid absorption, lipid absorption and lipase pancreatic activity, hepatic function, and protein absorption. (31). However the only test widely used in clinical practice is the ^{13}C urea BT for the diagnosis of *Helicobacter pylori* infection.

Since presently there are no practical and non-invasive methods for specific confirmation of SI deficiency conditions, we developed and validated a sucrose breath test for screening and confirmation of CSID using a novel non-invasive ^{13}C -sucrose labeled substrate. Our hypotheses were that primary sucrase deficiency can be confirmed using ^{13}C -sucrose breath test and that the effectiveness of sucrase replacement therapy can be evaluated by the same non-invasive method. The objectives of our investigation were to determine whether CSID can be detected with the ^{13}C -sucrose BT without duodenal biopsy sucrase assay and whether the ^{13}C -sucrose BT can document restoration of sucrose digestion in CSID patients after oral supplementation with yeast sucrase (Sucraid®).

METHODS

Clinical

After obtaining Institutional Review Board (IRB) approved informed consents under protocol H-10239, a total of 20 patients participated in this study. Ten CSID patients were diagnosed by intestinal enzyme activity determinations (5F: 5M, ages 1–15y) (Table 1). The CSID patients were recruited in three different ways: referral by Pediatric Gastroenterologists, direct self-referral by CSID families who called our study coordinator after reading an information letter about the study inserted in the Sucraide® package by QOL Medical Company; and families referred through the CSID website www.csidinfo.com. A control group of subjects was recruited from the Nutrition and Gastroenterology Service at Texas Children's Hospital (TCH). Ten controls (6F: 4M, ages 1–15 yrs) were patients who underwent endoscopy and biopsy because symptoms of dyspepsia or chronic diarrhea but with normal levels of mucosal enzymes measured according to the Dahlqvist method (36) and normal histology. The control group patients were participants of the IRB approved protocol H-1320 for recruiting children of both genders, 0–17 yrs with dyspepsia (ROME II criteria) and chronic diarrhea, pain or discomfort centered in the upper abdomen (37).

All CSID patients were biopsied and diagnosed by their primary GI physician before coming to the General Clinical Research Center (GCRC) at TCH for the BT study. In the control group the endoscopy procedures were performed for clinical indications by Pediatric Gastroenterologists at TCH. These biopsies were evaluated by the Pathology Department of TCH. Exclusion criteria for all subjects included villous atrophy on routine histology, fever, inability to cooperate with breath collections, failure to ingest the test ¹³C-solution, diabetes, and chronic lung disease.

Biopsy enzyme assay and histology

The disaccharidase enzyme activity determinations for the control group and some of the CSID patients were done at the GI lab of Buffalo Women and Children's Hospital in N.Y (1). The remainder of the CSID patient's biopsies were assayed in other reference labs with the histology interpreted locally.

Breath tests

The ¹³CO₂ breath tests were done on 2 separate days for the control group and on 3 separate days for the CSID group at the GCRC at the TCH under protocol G-695. After overnight fasting, a 2.5 L reference breath sample was collected for comparison with the timed breath samples. Then 20 mg uniformly-labeled ¹³C-glucose, (Isotec, Miamisberg, OH) was given using 10 gm unlabeled maltodextrins as carrier dissolved in water to a total volume of 100ml (Polycose® from Ross Division of Abbot Laboratories). Starting 15 minutes after the ¹³C-glucose load 0.25 L breath samples were collected every 15 minutes for 120 minutes. After finishing the BT the subject was fed and released from the GCRC. The second day the procedure was the same but ¹³C-sucrose was used. On the third day CSID patients had a repeat ¹³C-sucrose load with addition of 22 drops of Sucraide® (8,500 IU of sacrosidase, provided by QOL Medical, Mooresville, NC) to the load solution.

Breath ¹³CO₂ enrichment analysis

After ¹³C-labeled substrate loads were administered, breath collections and measurement of ¹³CO₂ enrichments were performed every 15 min × 9 using a ¹³CO₂ infrared spectrophotometer (POCone®, Otsuka Electronics, Tokyo, Japan). At each time point the total CO₂ concentration exceeded 2% in the breath sample and was thus in the ¹³CO₂ analytical range of the instrument. The BT results were recorded as total breath CO₂ concentration expressed as glucose-ΔOB ¹³CO₂ or sucrose-ΔOB ¹³CO₂.

Calculations

Because of the age related variations of glucose oxidation to CO_2 described below, glucose- $\Delta\text{OB}^{13}\text{CO}_2$ was used as denominator to overcome the effect of age on sucrose- $\Delta\text{OB}^{13}\text{CO}_2$. ^{13}C -sucrose digestion and oxidation was expressed as a % coefficient of glucose oxidation (% CGO) as calculated from $\Delta\text{OB}^{13}\text{CO}_2$ breath enrichments as follows:

$$\% \text{ CGO} = [\text{sucrose-}\Delta\text{OB}^{13}\text{CO}_2 / \text{glucose-}\Delta\text{OB}^{13}\text{CO}_2] \times 100$$

Since % CGO values were found relatively constant in the period of 30 to 90 minutes after the load these values were averaged for each individual. The individual subject mean % CGO values were used to identify the lower reference limit of ^{13}C -sucrose BT for controls and used to compare ^{13}C -sucrose BT of CSID with duodenal sucrase activities (see below).

Statistical procedures

Agreement between duodenal sucrase activity and ^{13}C -sucrose BT mean % CGO was tested with receiver operation analysis (ROC) using the statistics software SPSS. Additional subjects were recruited from the families of CSID patients for replicate ^{13}C -glucose and ^{13}C -sucrose BT to evaluate the within subject variations (Table 2) and to test the effect of age on glucose- $\Delta\text{OB}^{13}\text{CO}_2$ (Figure 1). General linear modeling techniques were used to assess possible effects of group age distribution differences on CGO% values and the ability of the breath test to discriminate between normal and CSID subjects. Two tail t-tests were used to compare groups; p values < 0.05 were interpreted as significant.

RESULTS

Clinical Description of CSID patients

Patients from the CSID group were referred by Pediatric Gastroenterologists. Their duodenal biopsy enzyme assays are shown in Table 1. Clinical histories varied but all CSID patients had duodenal biopsy sucrase activities below 6.5; all had maltase activities below 115; and 9 of 10 had palatinase activities below 5 U/g protein. None had villous atrophy.

Clinical Description of control subjects

Ten controls were children biopsied for clinical indications by the Pediatric Gastroenterology service at TCH because of the complaint of dyspepsia. All controls had levels of duodenal biopsy disaccharidase enzyme activities well above the reference levels (Table 1). None had mucosal histologic abnormalities.

Glucose oxidation with age

% CGO was used to normalize the sucrose- $\Delta\text{OB}^{13}\text{CO}_2$. The effect of age in months on glucose- $\Delta\text{OB}^{13}\text{CO}_2$ is shown in Figure 1. This analysis included 44 subjects by additional studies in CSID family members. 83% of the total variation of glucose- $\Delta\text{OB}^{13}\text{CO}_2$ was accounted for by the subject's age. (Figure 1, R^2 83%).

Replicate ^{13}C -glucose and ^{13}C -sucrose BT

On replicate BT testing of the same subject, separated by 1–12 months, a mean % coefficient of variation (% CV) of 14% for the ^{13}C -glucose BT and 9% for ^{13}C -sucrose BT were observed (Table 2).

^{13}C -sucrose oxidation in CSID and controls

In the control group an average of $146\% \pm 45.5$ mean % CGO and for the CSID group an average of 25 ± 21 mean % CGO were observed ($p < 0.001$) (Figure 2). The lowest mean %

CGO obtained was 0.7% and the highest was 56.5% in the CSID patients (Table 1). Analysis controlling for differences in group age distribution found no relationship between % CGO and age or any effect of age on the above group averages. Therefore age did not effect the assessment of the BT ability to discriminate.

Clinical utility of ^{13}C -sucrose BT mean % CGO

ROC analysis of mucosal biopsy sucrase activity vs. ^{13}C -sucrose mean % CGO established a cut-off value for ^{13}C -sucrose BT mean % CGO of 79% which yielded 100% sensitivity and 100% specificity (95% confidence interval 74% to 100% for both) for detection of low duodenal sucrase activity by ^{13}C -sucrose BT mean % CGO (Figure 2 and Figure 3).

Response of CSID patient's ^{13}C -sucrose BT to Sucraid® supplement

All CSID patients showed correction of sucrase deficiency with oral Sucraid® supplementation, responding to levels greater than their baseline ^{13}C -sucrose BT mean % CGO ($p = 0.001$) (Figure 3).

DISCUSSION

Duodenal Enzyme Activities

In this $^{13}\text{CO}_2$ BT study we included 10 CSID patients with biopsy proven sucrase deficiency and normal histology (Table 1). The $^{13}\text{CO}_2$ BT 9–14% coefficient of variation (CV%) of replicate BTs compares favorably with the 27 CV% of sucrase activity assayed reported in replicate duodenal biopsies (1). All CSID duodenal sucrase enzyme levels fell below the 10th % reference value (27 U/gp) in a range from 0 to 6.5 U/gp, and palatinase (isomaltase) levels were from 0 to 4.9 U/gp. Patient 7 had normal isomaltase activity (6.7 U/gp) (1). All CSID patients had low maltase activities. Patient 1 and patient 8, the only two with glucoamylase enzyme determinations, were below the 10% reference value. For terminal starch digestion mucosal enzymes in the brush border are armed with 4 complimentary maltase activities, two from the SI complex and 2 from MGAM. SI accounts for 60–80% of the assayed maltase hydrolytic activity and the remainder is due to MGAM (1). From this we deduce that the CSID patients with mild reductions of maltase activities are retaining some hydrolytic activity from MGAM. In patient 7, where isomaltase was conserved, this also contributed to maintenance of maltase activity.

Glucose oxidation with age

Studies using combined gas chromatography-mass spectrometry (38) and neuroimaging techniques-positron emission tomography (PET) (39) have shown that fasting child endogenous glucose production and brain glucose oxidation are two-to-four fold greater than in the adult. In our study we confirmed that glucose oxidation was two to four times higher in children than adults (Figure 1). This may be due to the unique glucose needs for child brain development as reflected by our ^{13}C -glucose BT results in children. Central nervous system glucose consumption represents 60–80% of daily hepatic glucose output in the child, as it does in the adult (40), suggesting the importance of a good carbohydrate digestion and absorption in early child neurodevelopment. Because of the age dependence of glucose oxidation, % CGO is a necessary normalization for the digestion, absorption and oxidation of sucrose in children.

Gastric emptying

Using the ^{13}C -glucose BT we addressed the uniformity of liquid phase of gastric emptying for our study. We used 10% maltodextrin (Polycose®) instead of water because maltodextrin made from corn is poorly isotopically enriched (0.2%) and provides a standard

osmotic and energy matrix for the uniformly enriched ^{13}C -labeled tracer substrate. The same dose of maltodextrins was used for each loading test to increase the uniformity of gastric emptying and the small amount of ^{13}C in the maltodextrin was thus blanked out in % CGO. The maltodextrin serves to standardize caloric load to mimic a meal and provide a trigger for liquid gastric emptying (41)

Test of Hypothesis 1

One of our objectives was to compare the less invasive ^{13}C -sucrose BT with duodenal biopsy sucrase assays obtained by endoscopy. A very strong relationship was observed and ROC analysis indicated that a reference value of 79 % mean % CGO discriminated between CSID and control populations, as confirmed by duodenal sucrase activities, with 100% sensitivity and 100% specificity (95% confidence interval 74% to 100% for both). This supports our first hypothesis that CSID can be confirmed with the ^{13}C -sucrose BT, however secondary sucrase deficiency cannot be excluded without clinical evaluation and biopsy.

Test of Hypothesis 2

We tested the ^{13}C -sucrose BT response to the enzyme supplement Sucraid® documenting a rise in mean % CGO for each CSID patient after the supplement to levels not different from controls ($P = 0.293$). The effectiveness of orally replacing sucrase was confirmed by the ^{13}C -sucrose BT. This response supports our second hypothesis that ^{13}C -sucrose BT quantitated the response of CSID patients to Sucraid® supplementation.

Non-invasive BT

One of the advantages of ^{13}C -sucrose BT which we and parents observed was that many CSID patients who had previous hydrogen BT experienced severe symptoms, passage of watery stools, bloating abdomen, and cramps from the 2 g/Kg sucrose load. We did not observe this symptomatic response in any CSID patient because the load of sucrose ingested was only 0.02 g for the ^{13}C -sucrose BT. As previously noted; the H_2 BT is not specific for sucrose malabsorption. With ^{13}C -sucrose BT we demonstrated a sensitivity and specificity of 100% (95% confidence interval 74% to 100% for both) in CSID patients and suggest that this diagnostic tool can be used as a non-invasive method for the confirmation and management of CSID.

SUMMARY

^{13}C -sucrose BT was evaluated as a non-invasive method for the confirmation of CSID. The results of sucrose digestion and oxidation were expressed as percentage of glucose oxidation (% CGO) and averaged between 30 and 90 minutes after the ^{13}C -substrate loads (mean % CGO). In controls and patients ^{13}C -sucrose BT mean % CGO agreed with duodenal sucrase enzyme activity determinations with 100% sensitivity and 100% specificity (95% confidence interval 74% to 100% for both). All CSID patients tested had ^{13}C -sucrose BT mean % CGO lower than 79%. Supplementation of CSID patients with sacrosidase enzyme corrected ^{13}C -sucrose BT mean % CGO to control levels.

Acknowledgments

We thank the Pediatric Gastroenterologists and Endoscopy Suite at Texas Children's Hospital for control subject referrals and Mary Lawson (www.csidinfo.com) and Pediatric Gastroenterologists around the nation for CSID referrals. This investigation was carried out at the NIH supported General Clinical Research Center at Texas Children's Hospital (M01-RR00188). CCRT was supported by Fogarty International Center of the National Institute of Health D43TW01036 and Children's Nutrition Research Center. BLN was supported by USDA/ARS Project # USDA 6250-51000-03400D and ARO by BCM Medicine GI 2233316101. Additional support was received from Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases

Center. ¹³C-sucrose was provided by a grant from Joli laboratories, Williamsville, NY. Sacrosidase was provided by QOL Medical, Mooresville, NC

References

1. Quezada-Calvillo R, Robayo-Torres CC, Ao Z, Hamaker BR, Quaroni A, Brayer GD, Sterchi EE, Baker SS, Nichols BL. Luminal substrate “brake” on mucosal maltase-glucoamylase activity regulates total rate of starch digestion to glucose. *J Pediatr Gastroenterol Nutr.* 2007; 45(1):32–43. [PubMed: 17592362]
2. Drozdowski LA, Thomson AB. Intestinal sugar transport. *World J Gastroenterol.* 2006; 12(11): 1657–1670. [PubMed: 16586532]
3. Weijers HA, van de Kamer JH, Mossel DA, Dicke WK. Diarrhoea caused by deficiency of sugar-splitting enzymes. *Lancet.* 1960 Aug 6;2:296–297. [PubMed: 13843498]
4. Anderson CM, Kerry KR, Townley RR. An inborn defect of intestinal absorption of certain monosaccharides. *Arch Dis Child.* 1965; 40:1–6. [PubMed: 14259267]
5. Ouwendijk J, Moolenaar CE, Peters WJ, Hollenberg CP, Ginsel LA, Fransen JA, Naim HY. Congenital sucrase-isomaltase deficiency. Identification of a glutamine to proline substitution that leads to a transport block of sucrase-isomaltase in a pre-Golgi compartment. *J Clin Invest.* 1996; 97(3):633–641. [PubMed: 8609217]
6. Naim HY, Roth J, Sterchi EE, Lentze M, Milla P, Schmitz J, Hauri HP. Sucrase-isomaltase deficiency in humans. Different mutations disrupt intracellular transport, processing, and function of an intestinal brush border enzyme. *J Clin Invest.* 1988; 82(2):667–679. [PubMed: 3403721]
7. Sander P, Alfalah M, Naim HY. Novel mutations in the human sucrase-isomaltase gene (SI) that cause congenital carbohydrate malabsorption. *Hum Mutat.* 2006; 27(1):119. [PubMed: 16329100]
8. Auricchio S, Rubino A, Prader A, Rey J, Jos J, Frezal J, Davidson M. Intestinal glycosidase activities in congenital malabsorption of disaccharides. *J Pediatr.* 965:555–564. 66.
9. Semenza G, Auricchio S, Rubino A, Prader A, Welsh JD. Lack of some intestinal maltases in a human disease transmitted by a single genetic factor. *Biochim Biophys Acta.* 1965; 24(105(2)):386–389. [PubMed: 5849827]
10. Skovbjerg H, Krasilnikoff PA. Maltase-glucoamylase and residual isomaltase in sucrose intolerant patients. *J Pediatr Gastroenterol Nutr.* 1986; 5(3):365–371. [PubMed: 3088247]
11. Treem WR. Clinical heterogeneity in congenital sucrase-isomaltase deficiency. *J Pediatr.* 1996; 128(6):727–729. [PubMed: 8648527]
12. Treem WR. Congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr.* 1995; 21(1):1–14. [PubMed: 8576798]
13. Karnsakul W, Nichols B. Disaccharidase activities in dyspeptic children: biochemical and molecular investigations of maltase-glucoamylase activity. *J Pediatr Gastroenterol Nutr.* 2002; 35(4):551–556. [PubMed: 12394383]
14. Gudmand-Hoyer E, Fenger HJ, Kern-Hansen P, Madsen PR. Sucrase deficiency in Greenland. Incidence and genetic aspects. *Scand J Gastroenterol.* 1987; 22(1):24–28. [PubMed: 3563408]
15. Nichols BL, Avery SE, Karnsakul W, Jahoor F, Sen P, Swallow DM, Luginbuehl U, Hahn D, Sterchi EE. Congenital maltase-glucoamylase deficiency associated with lactase and sucrase deficiencies. *J Pediatr Gastroenterol Nutr.* 2002; 35(4):573–579. [PubMed: 12394387]
16. Anderson CM, Messer M, Townley RR, Freeman M. Intestinal sucrase and isomaltase deficiency in two siblings. *Pediatrics.* 1963; 31:1003–1010. [PubMed: 14012820]
17. Harms HK, Bertele-Harms RM, Bruer-Kleis D. Enzyme-substitution therapy with the yeast *Saccharomyces cerevisiae* in congenital sucrase-isomaltase deficiency. *N Engl J Med.* 1987; 316(21):1306–1309. [PubMed: 3553946]
18. Treem WR, Ahsan N, Sullivan B, Rossi T, Holmes R, Fitzgerald J, Proujansky R, Hyams J. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. *Gastroenterology.* 1993; 105(4):1061–1068. [PubMed: 8405850]
19. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr.* 1999; 28(2):137–142. [PubMed: 9932843]

20. Davidson GP, Robb TA. Value of breath hydrogen analysis in management of diarrheal illness in childhood: comparison with duodenal biopsy. *J Pediatr Gastroenterol Nutr.* 1985; 4(3):381–387. [PubMed: 4020571]
21. Gibson GR, Cummings JH, Macfarlane GT, Allison C, Segal I, Vorster HH, Walker AR. Alternative pathways for hydrogen disposal during fermentation in the human colon. *Gut.* 1990; 31(6):679–683. [PubMed: 2379871]
22. Shreeve WW, Shoop JD, Ott DG, McIntee BB. Test for alcoholic cirrhosis by conversion of [¹⁴C]- or [¹³C]galactose to expired CO₂. *Gastroenterology.* 1976; 71(1):98–101. [PubMed: 1278655]
23. Caytan E, Botosoa EP, Silvestre V, Robins RJ, Akoka S, Remaud GS. Accurate quantitative ¹³C NMR spectroscopy: repeatability over time of site-specific ¹³C isotope ratio determination. *Anal Chem.* 2007; 79(21):8266–8269. [PubMed: 17900175]
24. Lemos PC, Dai Y, Yuan Z, Keller J, Santos H, Reis MA. Elucidation of metabolic pathways in glycogen-accumulating organisms with in vivo ¹³C nuclear magnetic resonance. *Environ Microbiol.* 2007; 9(11):2694–2706. [PubMed: 17922754]
25. Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G. Measurement of the rate of assimilation of oligo- and polysaccharides by ¹³CO₂ breath tests and isotope ratio mass spectrometry. *Biomed Environ Mass Spectrom.* 1988; 16(1–12):133–135. [PubMed: 3149533]
26. Christian MT, Amarri S, Franchini F, Preston T, Morrison DJ, Dodson B, Edwards CA, Weaver LT. Modeling ¹³C breath curves to determine site and extent of starch digestion and fermentation in infants. *J Pediatr Gastroenterol Nutr.* 2002; 34(2):158–164. [PubMed: 11840033]
27. Symonds EL, Kritis S, Omari TI, Butler RN. A combined ¹³CO₂/H₂ breath test can be used to assess starch digestion and fermentation in humans. *J Nutr.* 2004; 134(5):1193–1196. [PubMed: 15113969]
28. Irving CS, Klein PD, Navratil PR, Boutton TW. Measurement of ¹³CO₂/¹²CO₂ abundance by nondispersive infrared heterodyne ratiometry as an alternative to gas isotope ratio mass spectrometry. *Anal Chem.* 1986; 58(11):2172–2178. [PubMed: 3094401]
29. Braden B, Caspary WF, Lembcke B. Nondispersive infrared spectrometry for ¹³CO₂/¹²CO₂ - measurements: a clinically feasible analyzer for stable isotope breath tests in gastroenterology. *Z Gastroenterol.* 1999; 37(6):477–481. [PubMed: 10427653]
30. Kato M, Saito M, Fukuda S, Kato C, Ohara S, Hamada S, Nagashima R, Obara K, Suzuki M, Honda H, Asaka M, Toyota T. ¹³C-urea breath test, using a new compact nondispersive isotope-selective infrared spectrophotometer: comparison with mass spectrometry. *J Gastroenterol.* 2004; 39(7):629–634. [PubMed: 15293132]
31. Braden B, Lembcke B, Kuker W, Caspary WF. ¹³C-breath tests: current state of the art and future directions. *Dig Liver Dis.* 2007; 39(9):795–805. [PubMed: 17652042]
32. Maffei HV, Metz GL, Jenkins DJ. Hydrogen breath test: Adaptation of a simple technique to infants and children. *Lancet.* 1976; 1(7969):1110–1110. [PubMed: 57513]
33. Perman JA, Barr RG, Watkins JB. Sucrose malabsorption in children: noninvasive diagnosis by interval breath hydrogen determination. *Pediatr.* 1978; 93(1):17–22.
34. Koletzko B, Demmelmair H, Hartl W, Kindermann A, Koletzko S, Sauerwald T, Szitanyi P. The use of stable isotope techniques for nutritional and metabolic research in paediatrics. *Early Hum Dev.* 1998 Dec; 53(Suppl):S77–S97. [PubMed: 10102657]
35. Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G, de Buyser K. ¹³CO₂ breath test to measure the hydrolysis of various starch formulations in healthy subjects. *Gut.* 1990; 31(2):175–178. [PubMed: 2107133]
36. Dahlqvist A. Assay of intestinal disaccharidases. *Anal Biochem.* 1968; 22(1):99–107. [PubMed: 5636962]
37. Drossman, DA.; Corazziari, E.; Talley, NJ.; Thompson, WG.; Whitehead, WE. Rome II The Functional Gastrointestinal Disorders. 2nd edition. Degnon Associates Mc Lean; VA, USA: chapter 6; p. 302Functional Gastroduodenal Disorders
38. Bier DM, Leake RD, Haymond MW, Arnold KJ, Gruenke LD, Sperling MA, Kipnis DM. Measurement of "true" glucose production rates in infancy and childhood with 6,6-dideuteroglucose. *Diabetes.* 1977; 26(11):1016–1023. [PubMed: 913891]

39. Chugani HT. Biological basis of emotions: brain systems and brain development. *Pediatrics*. 1998; 102(5 Suppl E):1225–1229. [PubMed: 9794959]
40. Felig P. The glucose-alanine cycle. *Metabolism*. 1973; 22(2):179–207. [PubMed: 4567003]
41. Hunt JN, Smith JL, Jiang CL. Effect of meal volume and energy density on the gastric emptying of carbohydrates. *Gastroenterology*. 1985; 89(6):1326–1330. [PubMed: 4054524]




Figure 1. Effects of age on oral glucose breath test CO_2 enrichment

Effects of age in months on individual mean breath $^{13}\text{CO}_2 \Delta\text{OB}$ enrichments after a 20 mg ^{13}C -glucose load to controls, CSID patients and their family members. Breath enrichments of $^{13}\text{CO}_2 \Delta\text{OB} = 1/(\text{Age} * 3.38 \times 10^{-3} + 2.24 \times 10^{-2})$; $R^2 = 0.83$, $n = 44$. Predicted mean $^{13}\text{CO}_2 \Delta\text{OB}$ is shown as heavy black line \pm 95% CI thin lines.




Figure 2. Effects of CSID on oral sucrose breath test mean % CGO

Figure 2. Mean % CGO of individual subjects after a 20 mg ^{13}C -sucrose BT load and group means of all control and CSID subjects. The solid bar depicts the group average \pm SD of controls.

Individual values are shown as filled circles. The open bar depicts the average \pm SD of the CSID patients. Individual values are shown as open circles. The dashed line is the 79 % mean CGO reference value for discriminating between control and CSID subjects (see text).




Figure 3. Effects of oral sacrosidase supplementation of CSID patients on sucrose breath test mean % CGO

Mean % CGO of individual CSID patients untreated (Left) and treated (Right) with 22 drops of oral sacrosidase supplement added to the sucrose load ($p = 0.001$, $n = 9$). The dashed line is the 79 % mean CGO reference value for discriminating between normal and untreated CSID subjects (see text).

Table 1

Duodenal biopsy disaccharidase activities (U g/protein)

Reference Values (1)		6.5	26	89	5	32
Patient	Age	Lactase	Sucrase	Maltase	Palatinase	Glucosamylase
CSID 1	11m	91.5	0.3	28.1	2.3	5.4
CSID 2	15y	30.1	0	37.3	0	-
CSID 3	3y	43.1	0	39.4	0	-
CSID 4	2y	23.7	1.4	60.5	0	-
CSID 5	4y	126.4	3.6	93.9	1.8	-
CSID 6	4y	33.9	0.7	0	0.5	-
CSID 7	4y	23	0	0	6.7	-
CSID 8	23m	58.3	0	-	2	10.4
CSID 9	13m	53.3	6.5	50.9	4.9	-
CSID 10	11m	37.8	2.7	22.9	0	-
* Control	10 (2–15) yr	(23–126)	(35.5–96)	(115–268)	(5–16.5)	(95–110)

* Range of control group age and activities for each substrate

Table 2

Within individual ^{13}C -glucose and ^{13}C -sucrose BT mean $^{13}\text{CO}_2 \Delta\text{OB}$ replicate variations (% CV) after 20 mg ^{13}C -substrate oral loads.

	^{13}C-glucose BT % CV	^{13}C-sucrose BT % CV
Average \pm SD	13.5 ± 11.4	9.4 ± 7.1
Range	0–30	0–20
n	7	8



HHS Public Access

Author manuscript

Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2019 October 01.

Published in final edited form as:

Clin Gastroenterol Hepatol. 2018 October ; 16(10): 1673–1676. doi:10.1016/j.cgh.2018.01.047.

Increased Prevalence of Rare Sucrase-isomaltase (SI) Pathogenic Variants in Irritable Bowel Syndrome Patients

Koldo Garcia-Etxebarria^{*,‡,a}, Tenghao Zheng^{§,||,a}, Ferdinando Bonfiglio^{*,§}, Luis Bujanda^{*,¶}, Aldona Dlugosz[#], Greger Lindberg[#], Peter T. Schmidt[¶], Pontus Karling^{**}, Bodil Ohlsson^{‡‡}, Magnus Simren^{§§}, Susanna Walter^{¶¶¶}, Gerardo Nardone^{¶¶¶}, Rosario Cuomo^{##}, Paolo Usai-Satta^{***}, Francesca Galeazzi^{†††}, Matteo Neri^{§§§}, Piero Portincasa^{¶¶¶¶}, Massimo Bellini^{¶¶¶¶}, Giovanni Barbara^{###}, Daisy Jonkers^{****}, Shanti Eswaran^{††††}, William D. Chey^{††††}, Purna Kashyap^{§§§§}, Lin Chang^{¶¶¶¶¶}, Emeran A. Mayer^{¶¶¶¶¶}, Mira M. Wouters^{¶¶¶¶¶}, Guy Boeckxstaens^{¶¶¶¶¶}, Michael Camilleri^{####}, Andre Franke^{*****}, and Mauro D'Amato^{*,‡,||,‡‡‡‡}

^{*}Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain [‡]Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden [§]Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden ^{||}Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

[¶]Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain [#]Department of Medicine Solna, Karolinska Institutet, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden ^{**}Division of Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden ^{##}Lund University, Skåne University Hospital, Department of Internal Medicine, Lund, Sweden ^{¶¶}Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden ^{¶¶¶}Division of Neuro and Inflammation Science, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden ^{¶¶¶¶}Gastroenterology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy ^{##}Digestive Motility Diseases, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy ^{***}S.C. Gastroenterologia, Azienda Ospedaliera G. Brotzu, Cagliari, Italy ^{†††}UOC Gastroenterologia, Padova University Hospital, Padova, Italy ^{§§§}Department of Medicine and Aging Sciences and CESI, G. D'Annunzio University and Foundation, Chieti, Italy ^{¶¶¶¶}Department of Biomedical Sciences and Human Oncology (DIMO), Clinica Medica "A. Murri", University of Bari Medical School, Bari, Italy ^{¶¶¶¶}Gastroenterology Unit, Department of Gastroenterology, University of Pisa, Pisa, Italy ^{###}Department of Medical and Surgical Sciences, University of Bologna, St Orsola - Malpighi Hospital, Bologna, Italy ^{****}Department of Internal Medicine, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands ^{††††}Division of Gastroenterology, University of Michigan, Michigan Medicine, Ann

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Address requests for reprints to: Mauro D'Amato, Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet T2, SE-17176 Stockholm, Sweden. mauro.damato@ki.se; fax: +46-8-517 79304.

^aAuthors share co-first authorship.

Conflicts of interest

The project has been partially supported by an unrestricted research grant from QOL Medical to MDA.

Arbor, Michigan \$\$\$ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota ||||| G. Oppenheimer Center for Neurobiology of Stress and Resilience, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California ||||| Translational Research Center for Gastro Intestinal Disorders (TARGID), KU Leuven, Leuven, Belgium #### Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), and Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota **** Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany ##### IKERBASQUE, Basque Science Foundation, Bilbao, Spain

Patients with irritable bowel syndrome (IBS) often associate their symptoms to certain foods. In congenital sucrase-isomaltase deficiency (CSID), recessive mutations in the *SI* gene (coding for the disaccharidase digesting sucrose and 60% of dietary starch)¹ cause clinical features of IBS through colonic accumulation of undigested carbohydrates, triggering bowel symptoms.² Hence, in a previous study,³ we hypothesized that CSID variants reducing *SI* enzymatic activity may contribute to development of IBS symptoms. We detected association with increased risk of IBS for 4 rare loss-of-function variants typically found in (homozygous) CSID patients, because carriers (heterozygous) of these rare variants were more common in patients than in controls.^{1,4} Through a 2-step computational and experimental strategy, the present study aimed to determine whether other (dys-)functional *SI* variants are associated with risk of IBS in addition to known CSID mutations. We first aimed to identify all *SI* rare pathogenic variants (SI-RPVs) on the basis of integrated Mendelian Clinically Applicable Pathogenicity (M-CAP) and Combined Annotation Dependent Depletion (CADD) predictive (clinically relevant) scores; next, we inspected genotype data currently available for 2207 IBS patients from a large ongoing project to compare SI-RPV case frequencies with ethnically matched population frequencies from the Exome Aggregation Consortium (ExAC).

Methods

Study Subjects

A total of 2207 IBS patients (598 IBS with constipation [IBS-C], 952 IBS with diarrhea [IBS-D], 503 IBS with alternating constipation and diarrhea, and 154 unsubtyped IBS according to Rome Criteria) of European ancestry were included on the basis of available genotype data from the bellygenes initiative study (www.bellygenes.org). On approval from local ethical committees, IBS patients were recruited at tertiary centers in Sweden, The Netherlands, Belgium, Italy, and United States as described in detail in previous publications, including former genetic studies of IBS.^{5–8} Ethnically matched (non-Finnish, European ancestry; N = 33,370) reference population frequency of relevant SI-RVPs were extracted from ExAC (<http://exac.broadinstitute.org>).

Selection of Sucrase-isomaltase Rare Pathogenic Variants

An inventory of all *SI* rare variants (minor allele frequency <1%) was created by extracting single nucleotide polymorphism data from dbSNP (<http://www.ncbi.nlm.nih.gov/snp/>). Sequential data processing with M-CAP (<http://bejerano.stanford.edu/MCAP>) and CADD (<http://cadd.gs.washington.edu/>) was then performed to identify and select SI-RPVs. These computational resources were used because of their documented power to predict deleteriousness (pathogenicity) of DNA substitutions for clinical utility, assigning priority to M-CAP scores (pathogenicity cutoff >0.025, 5% misclassification rate) over CADD scores (pathogenicity cutoff >0.20, 26% misclassification rate).

Genotype Quality Control and Statistical Analysis

Before extraction of SI-RPV data, stringent quality control filters were applied to available IBS patients' Illumina HumanCoreExome genotype data, including per-sample and per-marker success rate, relatedness, and removal of population outliers based on principal component analysis. To avoid uncertainty, only observed (not imputed) SI-RPV genotypes were used, and allele calls were verified by visual inspection of individual cluster plots by using Evoker (www.sanger.ac.uk/science/tools/evoker). Population reference genotypes were only included for SI-RPVs with data available from >95% ExAC individuals. Association testing was performed by using one-tailed χ^2 statistics on collapsed SI-RPV data, comparing carriers and non-carriers in IBS patients compared with controls from ExAC.

Results

M-CAP/CADD combined analysis of all *SI* rare variants (N = 2146) resulted in the identification of 880 SI-RPVs with high predictive power (5% error rate for most variants). High-quality genotypes from IBS patients were available for 46 SI-RPVs, and 17 of these with at least 1 IBS carrier and ExAC reference data suitable for comparison were included in downstream association analyses (Table 1). We identified 88 IBS carriers (all single SI-RPV carriers; 3.99% of the entire cohort), with slightly higher prevalence in IBS-D (4.20%) and IBS-C (4.51%) than in other subtypes (Table 1). Compared with the large ethnically matched reference population from ExAC, most SI-RPVs occurred at higher frequency in IBS patients, and cumulative χ^2 tests (carriers of any SI-RPVs vs non-carriers) demonstrated significant associations and consistent effects on IBS risk (Table 1). In a simulation experiment, 1 million permutations of ExAC data resampled to match case sample size resulted >99% of the times in identical findings (SI-RPV carriers more common in IBS than in ExAC; $P < .001$).

Discussion

We provide further evidence linking rare functionally deleterious *SI* variations to IBS susceptibility. Although the large ExAC reference population (chosen to ensure genotype representation) does not include data on bowel symptoms, the observed association may represent an underestimation of the true genetic risk effects; the global prevalence of IBS is near 11%, and a significant proportion of ExAC individuals might thus be affected, with potential for inflating the background SI-RPV's carrier frequency among "controls"

compared with an otherwise symptom-free reference group (type II error). The consistent observation of higher SI-RPV prevalence in IBS warrants further studies. This has the potential to identify groups among IBS patients for individualized management.

Acknowledgments

Funding

Supported by grants from the Swedish Research Council (VR project nrs 2013-03862 and 2017-02403), the Health Department of the Basque Government (grant 2015111133), the Spanish Ministry of Economy and Competitiveness (ISCIII grant FIS PI17/00308), and an unrestricted research grant from QOL Medical to MDA.

Abbreviations used in this paper

CADD	Combined Annotation Dependent Depletion
CSID	congenital sucrase-isomaltase deficiency
ExAC	Exome Aggregation Consortium
IBS	irritable bowel syndrome
IBS-C	IBS with constipation
IBS-D	IBS with diarrhea
M-CAP	Mendelian Clinically Applicable Pathogenicity
SI-RPV	<i>SI</i> rare pathogenic variants

References

1. Diaz-Sotomayor M, Quezada-Calvillo R, Avery SE, et al. Maltase-glucoamylase modulates gluconeogenesis and sucrase-isomaltase dominates starch digestion glucogenesis. *J Pediatr Gastroenterol Nutr.* 2013; 57:704–712. [PubMed: 23838818]
2. Naim HY, Heine M, Zimmer K-P. Congenital sucrase-isomaltase deficiency: heterogeneity of inheritance, trafficking, and function of an intestinal enzyme complex. *J Pediatr Gastroenterol Nutr.* 2012; 55:S13–S20. [PubMed: 23103643]
3. Henström M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut.* 2016; 0:1–8. DOI: 10.1136/gutjnl-2016-312456
4. Uhrich S, Wu Z, Huang J-Y, et al. Four mutations in the SI gene are responsible for the majority of clinical symptoms of CSID. *J Pediatr Gastroenterol Nutr.* 2012; 55:S34–S35. [PubMed: 23103650]
5. Ek WE, Reznichenko A, Ripke S, et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. *Gut.* 2015; 64:1774–1782. [PubMed: 25248455]
6. Beyder A, Mazzone A, Stuge PR, et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (Channelopathies) in patients with irritable bowel syndrome. *Gastroenterology.* 2014; 146:1659–1668. [PubMed: 24613995]
7. Wouters MM, Lambrechts D, Knapp M, et al. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. *Gut.* 2014; 63:1103–1111. [PubMed: 24041540]

8. Mujagic Z, Tigchelaar EF, Zhernakova A, et al. A novel biomarker panel for irritable bowel syndrome and the application in the general population. *Sci Rep.* 2016; 6:26420. [PubMed: 27263852]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Prevalence of SI-RPVs in IBS Patients and ExAC Reference Individuals

Table 1

SNP	Reference allele	RPV	Amino acid change	M-CAP score	CADD score	SI-RPV carriers					
						IBS (N = 2207)		IBS-C (N = 598)		IBS-D (N = 952)	
						N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
rs200745562	G	A	p.Arg250Cys	0.152	3 (0.14)	1 (0.17)	2 (0.21)	—	—	—	15 (0.04)
rs77546399	G	A	p.Pro348Leu	0.417	12 (0.54)	4 (0.67)	6 (0.63)	1 (0.20)	1 (0.65)	1 (0.65)	149 (0.45)
rs138434001	C	T	p.Val371Met	0.412	8 (0.36)	2 (0.33)	1 (0.11)	4 (0.80)	1 (0.65)	1 (0.65)	153 (0.46)
rs142789249	T	C	p.Glu640Gly	0.039	2 (0.09)	1 (0.17)	1 (0.11)	—	—	—	18 (0.05)
rs188320908	A	T	p.Val717Asp	0.308	1 (0.05)	1 (0.17)	—	—	—	—	7 (0.02)
rs147207752	T	C	p.Arg774Gly	0.113	10 (0.45)	5 (0.84)	4 (0.42)	1 (0.20)	—	—	79 (0.24)
rs140230726	A	G	p.Tyr867His	0.142	1 (0.05)	—	—	1 (0.20)	—	—	14 (0.04)
rs146785675	A	G	p.Tyr975His	26.6	36 (1.63)	13 (2.17)	17 (1.79)	4 (0.80)	2 (1.30)	382 (1.4)	382 (1.14)
rs200451408	G	A	p.Arg124Stop	37	1 (0.05)	—	1 (0.11)	—	—	—	8 (0.02)
rs78013297	G	A	p.Pro120Ser	0.389	1 (0.05)	—	1 (0.11)	—	—	—	1 (0.03)
rs143388292	T	C	p.Arg1367Gly	0.17	2 (0.09)	—	2 (0.21)	—	—	—	28 (0.08)
rs145734588	C	T	p.Glu1414Lys	0.075	3 (0.14)	—	1 (0.11)	2 (0.40)	—	—	8 (0.02)
rs142090504	A	C	p.Tyr1417Stop	36	1 (0.05)	—	—	—	1 (0.65)	6 (0.02)	6 (0.02)
rs145246112	C	T	p.Arg1484His	0.293	1 (0.05)	—	—	—	1 (0.65)	19 (0.06)	19 (0.06)
rs149414344	A	C	p.Phe1625Val	0.057	1 (0.05)	—	1 (0.11)	—	—	—	1 (0.003)
rs142018224	C	G	p.Val667Leu	0.032	2 (0.09)	—	1 (0.11)	1 (0.20)	—	—	20 (0.06)
rs145556619	C	A	p.Gly1760Val	0.204	3 (0.14)	—	2 (0.21)	1 (0.20)	—	—	20 (0.06)
Total					88 (3.99)	27 (4.51)	40 (4.20)	15 (2.98)	6 (3.90)	928 (2.78)	
P value					.00049	.0055	.0045	.39	.21		
Odds ratio (95% confidence interval)					1.45 (1.16-1.81)	1.65 (1.12-2.44)	1.33 (1.11-2.12)	1.07 (0.64-1.80)	0.71 (0.31-1.60)		

Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2019 October 01.

CADD, Combined Annotation Dependent Depletion; ExAC, Exome Aggregation Consortium; IBS, irritable bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea; IBS-M, IBS with alternating constipation and diarrhea; IBS-U, unsubtyped IBS; M-CAP, Mendelian Clinically Applicable Pathogenicity; SI-RPV, sucrase-isomaltase rare pathogenic variants; SNP, single nucleotide polymorphism.

RESEARCH ARTICLE

Hypomorphic *SI* genetic variants are associated with childhood chronic loose stools

Bruno P. Chumpitazi^{1*}, Jeffery Lewis², Derick Cooper³, Mauro D'Amato⁴, Joel Lim⁵, Sandeep Gupta⁶, Adrian Miranda⁷, Natalie Terry⁸, Devendra Mehta⁹, Ann Scheimann¹⁰, Molly O'Gorman¹¹, Neelesh Tipnis¹², Yinka Davies¹³, Joel Friedlander¹⁴, Heather Smith³, Jaya Punati¹⁵, Julie Khlevner¹⁶, Mala Setty¹⁷, Carlo Di Lorenzo¹⁸



OPEN ACCESS

Citation: Chumpitazi BP, Lewis J, Cooper D, D'Amato M, Lim J, Gupta S, et al. (2020) Hypomorphic *SI*/genetic variants are associated with childhood chronic loose stools. PLoS ONE 15(5): e0231891. <https://doi.org/10.1371/journal.pone.0231891>

Editor: Adriana Calderaro, Università degli Studi di Parma, ITALY

Received: December 9, 2019

Accepted: April 2, 2020

Published: May 20, 2020

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0231891>

Copyright: © 2020 Chumpitazi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

1 Baylor College of Medicine, Houston, TX, United States of America, **2** Children's Center for Digestive Health Care, Atlanta, GA, United States of America, **3** QOL Medical, LLC, Vero Beach, FL, United States of America, **4** School of Biological Sciences, Monash University, Clayton, VIC, Australia, **5** Children's Mercy Hospital, Kansas City, MO, United States of America, **6** Sacramento Pediatric Gastroenterology, Sacramento, CA, United States of America, **7** Children's Hospital of Wisconsin, Milwaukee, WI, United States of America, **8** Children's Hospital of Philadelphia, Philadelphia, PA, United States of America, **9** Arnold Palmer Children's Hospital, Orlando, FL, United States of America, **10** Johns Hopkins University, Baltimore, MD, United States of America, **11** Primary Children's Medical Center, Salt Lake City, UT, United States of America, **12** University of Mississippi Medical Center, Jackson, MS, United States of America, **13** Sacramento Pediatric Gastroenterology, Sacramento, CA, United States of America, **14** Children's Hospital Colorado, Digestive Health Institute, University of Colorado School of Medicine, Aurora, CO, United States of America, **15** Children's Hospital of Los Angeles, Los Angeles, CA, United States of America, **16** Columbia University Medical Center, New York, NY, United States of America, **17** UCSF Benioff Children's Hospital Oakland, Oakland, CA, United States of America, **18** Department of Pediatrics, The Ohio State University, Columbus, OH, United States of America

✉ These authors contributed equally to this work.

* chumpita@bcm.edu

Abstract

Objective

The *SI* gene encodes the sucrase-isomaltase enzyme, a disaccharidase expressed in the intestinal brush border. Hypomorphic *SI* variants cause recessive congenital sucrase-isomaltase deficiency (CSID) and related gastrointestinal (GI) symptoms. Among children presenting with chronic, idiopathic loose stools, we assessed the prevalence of CSID-associated *SI* variants relative to the general population and the relative GI symptom burden associated with *SI* genotype within the study population.

Methods

A prospective study conducted at 18 centers enrolled 308 non-Hispanic white children ≤ 18 years old who were experiencing chronic, idiopathic, loose stools at least once per week for >4 weeks. Data on demographics, GI symptoms, and genotyping for 37 *SI*/hypomorphic variants were collected. Race/ethnicity-matched *SI* data from the Exome Aggregation Consortium (ExAC) database was used as the general population reference.

Funding: QOL Medical, LLC (<https://www.qolmed.com/>), funded the entire study. The funders participated in the study design, analyses, and critical review of the manuscript but had no role in data collection, decision to publish, or preparation of the manuscript.

Competing interests: Co-authors DC and HS are members of QOL Medical, LLC. QOL Medical LLC markets the product sacrosidase oral solution. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Results

Compared with the general population, the cumulative prevalence of hypomorphic *SI*/variants was significantly higher in the study population (4.5% vs. 1.3%, $P < .01$; OR = 3.5 [95% CI: 6.1, 2.0]). Within the study population, children with a hypomorphic *SI*/variant had a more severe GI symptom burden than those without, including: more frequent episodes of loose stools ($P < .01$), higher overall stool frequency ($P < .01$), looser stool form ($P = .01$) and increased flatulence ($P = .02$).

Conclusion

Non-Hispanic white children with chronic idiopathic loose stools have a higher prevalence of CSID-associated hypomorphic *SI*/variants than the general population. The GI symptom burden was greater among the study subjects with a hypomorphic *SI*/variant than those without hypomorphic *SI*/variants.

Introduction

A large number of children around the world experience chronic gastrointestinal (GI) symptoms diagnosed as functional (nonorganic) GI disorders [1]. Functional GI disorders may have several contributing pathophysiologic factors, including carbohydrate malabsorption [2]. The sucrase-isomaltase enzyme, encoded by the *SI* gene, is a predominant member of the disaccharidases responsible for the digestion of dietary carbohydrates in humans [3]. Hypomorphic *SI* gene variants reduce enzyme activity, resulting in congenital sucrase-isomaltase deficiency (CSID) and characteristic GI symptoms. To date, 37 *SI* variants have been identified in diagnosed CSID patients and found to be hypomorphic [4–12]. Patients with CSID experience sucrose malabsorption, leading to colonic osmosis and fermentation, and subsequent osmotic diarrhea and excessive flatulence [4, 13]. Heterozygotes of hypomorphic *SI* variants may also experience GI symptoms. Small case reports have associated hypomorphic *SI* heterozygosity with decreased intestinal sucrase enzymatic activity and characteristic GI symptoms [3, 12, 14]. In two recent studies, the prevalence of heterozygous carriers of hypomorphic *SI* variants was small but significantly greater among adults diagnosed with irritable bowel syndrome (IBS) than in controls, suggestive of an increased IBS susceptibility [15, 16].

A subset of children with functional GI disorders has frequent diarrhea. Currently, the potential contribution of hypomorphic *SI* variants in these children is unknown. Therefore, we had two primary study objectives. The first study objective was to determine the relative prevalence of hypomorphic *SI* variants among children with chronic, idiopathic, loose stools versus the general population. The second study objective in children with chronic, idiopathic, loose stools was to determine the potential impact of hypomorphic *SI* variants on symptom burden.

Methods

Study design and subjects

A prospective, 18-center study conducted in the United States enrolled subjects ≤ 18 years old who presented at a pediatric gastroenterology center with loose stools at least once per week for a minimum of 4 weeks.

The study objectives were i) to determine the prevalence of hypomorphic *SI* variants within the study population versus a genetic database for the general population, and ii) to determine the symptom burden among the study subjects with hypomorphic *SI* variants versus study subjects without hypomorphic *SI* variants.

Exclusion criteria included: identification of any condition(s) or finding(s) that, in the opinion of the investigator, suggested an organic etiology for the subject's GI symptoms; abdominal pain primarily related to constipation; suspected GI infectious disease or other infectious diseases; known GI disease (eg, celiac disease); a history of antibiotic therapy or viral gastroenteritis within the previous 2 weeks; known hepatitis B or C infection or chronic liver disease; cancer or systemic infections; severe neurologic impairment (preventing reporting of symptoms); planned or previous abdominal surgery (eg, bowel resection); severe, uncontrolled systemic diseases; or current use of sacrosidase, an enzyme replacement therapy for CSID.

The pediatric gastroenterology centers in this study were comprised of private practices and academic centers. Each investigator was asked to follow his or her standard clinical practice to ensure an organic etiology was not present. Evaluations took place during a clinic visit. All participating centers received approval from their local institutional review boards (IRB). The institutional review boards included: Baylor College of Medicine IRB, Children's Hospital Los Angeles Committee on Clinical Investigators, Nationwide Children's Hospital IRB, Children's Mercy Hospital Pediatric IRB, Johns Hopkins IRB, The Children's Hospital of Philadelphia Research Institute IRB, The Arnold Palmer Medical Center IRB, The Duke University Health System IRB, Massachusetts General Hospital IRB, Children's Hospital of Wisconsin IRB, Colorado Multiple IRB, The Indiana University IRB, Children's Healthcare of Atlanta IRB, The University of Utah IRB, Children's Hospital & Research Center Oakland IRB, University of Mississippi Medical Center IRB, Columbia University Medical Center IRB, and Sutter Health IRB. All subjects provided assent with a legal guardian providing written informed consent. The study was conducted from May 2013 to July 2015. All authors had access to the study data and approved the final manuscript.

Genotyping

Four buccal swabs were obtained for DNA extraction; genotyping of the 37 known CSID-associated variants ([S1 Table](#)) was completed by a validated capillary electrophoresis assay (SNAP-shot; Laboratory Corporation of America, Research Triangle Park, NC). Intra-assay reproducibility was assessed on 12-sample runs in 3 separate, replicate assays, with samples representing the 37 known hypomorphic variants of the *SI* gene associated with CSID. The reported prevalence of CSID-associated variants included subjects with simple heterozygous, compound heterozygous, and homozygous *SI* variant genotypes. Subjects without hypomorphic *SI* variants did not have any of the 37 analyzed CSID-associated variants on either allele.

The reference for the cumulative prevalence of hypomorphic *SI* variants in the general population was obtained from the Exome Aggregation Consortium (ExAC) database [15]. As the ExAC database data has now been incorporated into the gnomAD project, the evaluated ExAC data is currently available via a legacy link (<https://console.cloud.google.com/storage/browser/gnomad-public/legacy>). For this study, *SI* sequencing data for 32,550 unrelated non-Hispanic white individuals was retrieved from the ExAC database. The ExAC database provides publicly available genetic data from thousands of unrelated individuals of various races/ethnicities, from aggregated disease-specific and population genetic studies. The ExAC database has been used as a control for genetic studies evaluating a wide range of GI disorders, including adult IBS [15–18].

Symptom assessment

Subjects were asked to complete a demographic and symptom questionnaire to capture gender, age, race/ethnicity, and episodes of GI symptoms. All GI symptoms (abdominal pain, diarrhea, excessive flatus) were assessed using a study-specific questionnaire, including frequency, duration, and severity of bowel complaints ([S2 Table](#)). The GI symptom burden of the ExAC reference population is unknown.

Stool form was assessed using the modified Bristol Stool Form Scale (BSFS; categories 1–5) for children, with higher scores corresponding to looser stools [19]. The symptom questionnaire was generally given to children aged >7 years, with a parent otherwise providing answers.

Statistical analyses

Results are presented using descriptive statistics, including mean \pm standard deviation for continuous data and prevalence and/or percentages for categorical data. The cumulative prevalence of hypomorphic *SI* variants in this study population was compared with a race/ethnicity-matched ExAC prevalence using the Pearson's chi-squared test. Reported *P*-values are one-tailed, and *P* < .05 was considered statistically significant. Increased risk was estimated using the odds ratio (OR) with a 95% confidence interval (CI).

Results

Population characteristics

Three hundred and eight non-Hispanic white children with chronic, idiopathic, loose stools were enrolled and assessed. There was a slight predominance of boys (58%). Diarrhea, defined as chronic loose stools, was identified as the primary GI symptom.

Prevalence of hypomorphic *SI* variants

Among the 308 subjects, 14 had at least 1 hypomorphic *SI* variant, for a prevalence of 4.5%. Study subjects had a statistically significantly higher prevalence of hypomorphic *SI* variants than the race/ethnicity-matched general population (4.5% vs. 1.3%, *P* < .01; OR = 3.5; 95% CI: 6.1, 2.0) ([Table 1](#)).

Thirteen of the 14 subjects with an identified hypomorphic *SI* variant were simple heterozygous genotypes (93%), and one subject had a compound heterozygous genotype. Five distinct hypomorphic *SI* variants were identified among these 14 study subjects; 4 of these 5 distinct hypomorphic *SI* variants are the most common *SI* variants found in patients diagnosed with CSID (G1073D, V577G, R1124x and F1745C; [Table 2](#)) [12]. There were no statistically significant differences between the prevalence of hypomorphic *SI* variants in male and female subjects (4.5% and 4.7%, respectively).

Symptom burden associated with hypomorphic *SI* variants

Mean differences in the symptom burden of subjects with a hypomorphic *SI* variant versus subjects without a hypomorphic *SI* variant are reported in [Table 3](#). Compared with the 294 subjects without a hypomorphic *SI* variant, the 14 with a hypomorphic *SI* variant had significantly more frequent GI symptoms, including: more frequent weekly episodes of loose stools (*P* < .01), higher daily overall stool frequency (*P* < .01), looser stool form (*P* = .01) and increased flatulence (*P* = .02). Subjects with a hypomorphic *SI* variant also were younger (*P* < .01).

Table 1. Relative prevalence of hypomorphic *SI* variants.

	Study Population		ExAC Population		P-Value	OR	95% CI	
	Number	Prevalence	Number	Prevalence			Upper	Lower
Wild-type <i>SI</i>	294	95.5%	32,116	98.7%				
Hypomorphic <i>SI</i> variant ^a	14	4.5%	434	1.3%				
Total	308		32,550		< .01	3.5	6.1	2.1

^aIncludes one compound heterozygote in the study population.

<https://doi.org/10.1371/journal.pone.0231891.t001>

Discussion

We found hypomorphic *SI* variants among a study population of non-Hispanic white children with chronic, idiopathic, loose stools. The prevalence of these known hypomorphic *SI* variants was significantly higher in this study population compared to a race/ethnicity-matched general population. In addition, study subjects with a hypomorphic *SI* variant had a greater GI symptom burden than study subjects without hypomorphic *SI* variants. These findings add to the growing evidence suggesting heterozygous *SI* hypomorphic variants are associated with the development of CSID-associated GI symptoms.

The most common hypomorphic *SI* variants in our study cohort were also the hypomorphic *SI* variants most commonly identified in other genetic studies of individuals diagnosed with CSID [12]. Although the biochemical and functional effects of several *SI* variants have been well characterized and found to diminish sucrase and isomaltase function [4, 5, 8], the potential effect of a heterozygous genotype of a hypomorphic *SI* variant is still being studied and remains to be fully elucidated. Using either the duodenal disaccharidase enzyme assay or the ¹³C breath test to determine the extent of sucrase enzyme activity, family members of patients with CSID (with either presumed or well-documented heterozygosity for a hypomorphic *SI* variant) have been found to have decreased sucrase enzyme activity [14, 20]. Further supporting the potential pathobiological effect of heterozygous genotypes of hypomorphic *SI* variants are recent findings by Henström et al and Garcia-Etxebarria et al, who reported that heterozygous *SI* gene variants may be associated with an increased risk for diagnosis of adult IBS [15, 16]. Nevertheless, further prospective clinical evaluations including identification of heterozygous hypomorphic *SI* variants, functional measurements of sucrase-isomaltase (e.g., enzyme assays), controlled dietary exposures, and basic cellular and molecular based studies are needed to more clearly determine the role of hypomorphic *SI* heterozygous genotypes.

Table 2. Hypomorphic *SI* variants identified in the study population.

SI Variants	Rs	Grantham Score ^a	Subjects (N = 308)
G1073D ^b	121912616	94	7
V577G ^{b,c}	121912615	109	5 ^c
F1745C ^b	79717168	205	1
R1124x ^b	N/A	N/A	1
I1378S ^c	148831941	142	1 ^c
Total Unique Subjects			14 ^c

^aGrantham score is a measure of evolutionary distance in amino acid substitutions, classified by increasing chemical dissimilarity. A higher score reflects a higher likelihood that a substitution will be deleterious based on four general rankings: conservative (0–50), moderately conservative (51–100), moderately radical (101–150), or radical (≥ 151)

^bOne of the four most common CSID variations

^cOne participant was a compound heterozygote with both a V577G and an I1378S variant.

<https://doi.org/10.1371/journal.pone.0231891.t002>

Table 3. Symptom burden of study subjects by *SI* genotype.

	Total study population	With Hypo-morphic <i>SI</i> Variant	Without Hypo-morphic <i>SI</i> Variants	Mean Difference	P-value
Study subjects	308	14	294		
Age (mean yr)	7.6	3.8	7.7	4.0	< .01
Symptom Burden (mean)					
Symptom duration (mo)	8.8	8.6	8.9	0.3	NS
Diarrhea episode (d/wk)	5.1	6.6	5.0	1.6	< .01
Stools (#/d)	3.4	5.3	3.3	1.9	< .01
Pediatric BSFS, last diarrheal event	4.3	4.7	4.3	0.4	.01
2Abdominal pain (d/wk)	3.6	3.6	3.6	—	NS
Pain events (#/d)	1.4	1.4	1.4	—	NS
Pain severity (6-point VAS)	2.4	2.4	2.4	—	NS
Gas (d/wk)	4.9	6.3	4.9	1.4	.02
Gas events (#/d)	1.9	2.1	1.9	0.3	NS

BSFS, modified Bristol Stool Form Scale for children (categories 1–5, higher scores corresponding to looser stools); NS, not statistically significant; VAS, visual analog scale, 0–5

<https://doi.org/10.1371/journal.pone.0231891.t003>

Identifying the underlying factors contributing to functional GI symptoms is important as this knowledge may lead to more effective therapies. Children with CSID have been shown to benefit from a sucrose-restricted diet and enzyme replacement therapy with sacrosidase taken with meals [21–24]. Gastrointestinal symptoms related to diminished sucrase-isomaltase activity are primarily correlated with factors such as the extent of functional intestinal enzyme activity present and the amount of sucrose and/or starch ingested [4, 13]. It should be noted that in one study, a child with a heterozygous genotype of a hypomorphic *SI* variant, who was a sibling of a CSID-diagnosed subject, was asymptomatic [10]. Future studies in this area may consider assessing both enzyme activity and dietary intake relative to *SI* hypomorphic variants and the associated GI symptom burden.

There are a few limitations to this study. One limitation is that the age-, gender-, and race/ethnicity-matched control population was not actively recruited. However, even though the GI symptoms associated with the database entries are unknown, the ExAC reference database of a significantly large population allowed for a race/ethnicity-matched comparison. Second, the entire *SI* gene was not sequenced in participants. This opens the possibility—however unlikely—that some of the study subjects identified as lacking a hypomorphic *SI* variant had one or more hypomorphic *SI* variants in an uninvestigated portion of the *SI* gene. In addition, some of the study subjects identified as having a simple heterozygous genotype of a hypomorphic *SI* variant may also have a hypomorphic *SI* variant in an uninvestigated portion of the *SI* gene.

There are several strengths in the study. First, this multicenter effort was, to our knowledge, the largest of its kind in children with functional GI symptoms. Second, *SI* genotyping focused on 37 CSID-associated *SI* variants that have been well characterized biochemically as hypomorphic in prior studies. This leads to greater plausibility of the results. Third, the study was conducted in various academic and private practice settings, which will lead to greater generalizability of our findings.

Conclusion

In conclusion, we found CSID-associated hypomorphic *SI* variants in a study population of non-Hispanic white children with chronic, idiopathic, loose stools. These CSID-associated hypomorphic *SI* variants were found to occur at a significantly higher prevalence than that

reported in a race/ethnicity-matched reference population. Subjects with hypomorphic *SI* variants had more GI symptoms of frequent diarrhea and gas, a higher stool frequency, and looser stools compared to those in the study population without hypomorphic *SI* variants.

Supporting information

S1 Table. Hypomorphic *SI* Variants Identified in children with chronic gastrointestinal symptoms. Ala, alanine; Arg, arginine; Asp, aspartate; Cys, cysteine; Gln, glutamine; Glu, glutamate; Gly, glycine; I, isomaltase; Ile, isoleucine; Leu, leucine; N/A, not available; Phe, phenylalanine Pro, proline; S, sucrase; Ser, serine; Thr, threonine; Tyr, tyrosine; Trp, tryptophan; Val, valine. (DOCX)

S2 Table. Study questionnaire.

(DOCX)

S1 Data.

(XLSX)

Acknowledgments

We would like to acknowledge all investigators, coordinators, and study site personnel, as well as patients and their families for their participation in this study.

Author Contributions

Conceptualization: Bruno P. Chumpitazi, Derick Cooper.

Data curation: Jeffery Lewis, Derick Cooper, Mauro D'Amato, Joel Lim, Sandeep Gupta, Adrian Miranda, Natalie Terry, Devendra Mehta, Ann Scheimann, Molly O'Gorman, Neelesh Tipnis, Yinka Davies, Joel Friedlander, Jaya Punati, Julie Khlevner, Mala Setty, Carlo Di Lorenzo.

Formal analysis: Derick Cooper, Mauro D'Amato.

Funding acquisition: Derick Cooper.

Investigation: Bruno P. Chumpitazi.

Methodology: Bruno P. Chumpitazi, Jeffery Lewis, Derick Cooper, Mauro D'Amato, Joel Lim, Sandeep Gupta, Adrian Miranda, Natalie Terry, Devendra Mehta, Ann Scheimann, Molly O'Gorman, Neelesh Tipnis, Yinka Davies, Joel Friedlander, Heather Smith, Jaya Punati, Julie Khlevner, Mala Setty, Carlo Di Lorenzo.

Supervision: Derick Cooper.

Writing – original draft: Bruno P. Chumpitazi.

Writing – review & editing: Bruno P. Chumpitazi, Jeffery Lewis, Derick Cooper, Mauro D'Amato, Joel Lim, Sandeep Gupta, Adrian Miranda, Natalie Terry, Devendra Mehta, Ann Scheimann, Molly O'Gorman, Neelesh Tipnis, Yinka Davies, Joel Friedlander, Heather Smith, Jaya Punati, Julie Khlevner, Mala Setty, Carlo Di Lorenzo.

References

1. Chumpitazi BP, Shulman RJ. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. *Mol Cell Pediatr.* 2016; 3(1):11. <https://doi.org/10.1186/s40348-016-0036-8> PMID: 26883355

2. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. *Gastroenterology*. 2016; 150(6):1456–68. <https://doi.org/10.1053/j.2016.02015>
3. Naim HY, Roth J, Sterchi EE, Lentze M, Milla P, Schmitz J, et al. Sucrase-isomaltase deficiency in humans. Different mutations disrupt intracellular transport, processing, and function of an intestinal brush border enzyme. *J Clin Invest*. 1988; 82(2):667–79. <https://doi.org/10.1172/JCI113646> PMID: 3403721
4. Naim HY, Heine M, Zimmer KP. Congenital sucrase-isomaltase deficiency: heterogeneity of inheritance, trafficking, and function of an intestinal enzyme complex. *J Pediatr Gastroenterol Nutr*. 2012; 55(suppl 2):S13–20. <https://doi.org/10.1097/01.mpg.0000421402.57633.4b> PMID: 23103643
5. Alfallah M, Keiser M, Leeb T, Zimmer KP, Naim HY. Compound heterozygous mutations affect protein folding and function in patients with congenital sucrase-isomaltase deficiency. *Gastroenterology*. 2009; 136(3):883–92. <https://doi.org/10.1053/j.gastro.2008.11.038> PMID: 19121318
6. Gericke B, Amiri M, Naim HY. The multiple roles of sucrase-isomaltase in the intestinal physiology. *Mol Cell Pediatr*. 2016; 3(1):2. <https://doi.org/10.1186/s40348-016-0033-y> PMID: 26812950
7. Jacob R, Zimmer KP, Schmitz J, Naim HY. Congenital sucrase-isomaltase deficiency arising from cleavage and secretion of a mutant form of the enzyme. *J Clin Invest*. 2000; 106(2):281–7. <https://doi.org/10.1172/JCI9677> PMID: 10903344
8. Keiser M, Alfallah M, Propsting MJ, Castelletti D, Naim HY. Altered folding, turnover, and polarized sorting act in concert to define a novel pathomechanism of congenital sucrase-isomaltase deficiency. *J Biol Chem*. 2006; 281(20):14393–9. <https://doi.org/10.1074/jbc.M513631200> PMID: 16543230
9. Ritz V, Alfallah M, Zimmer KP, Schmitz J, Jacob R, Naim HY. Congenital sucrase-isomaltase deficiency because of an accumulation of the mutant enzyme in the endoplasmic reticulum. *Gastroenterology*. 2003; 125(6):1678–85. <https://doi.org/10.1053/j.gastro.2003.09.022> PMID: 14724820
10. Sander P, Alfallah M, Keiser M, Korponay-Szabo I, Kovacs JB, Leeb T, et al. Novel mutations in the human sucrase-isomaltase gene (*S*) that cause congenital carbohydrate malabsorption. *Human Mutat*. 2006; 27(1):119. <https://doi.org/10.1002/humu.9392> PMID: 16329100
11. Spodsberg N, Jacob R, Alfallah M, Zimmer KP, Naim HY. Molecular basis of aberrant apical protein transport in an intestinal enzyme disorder. *J Biol Chem*. 2001; 276(26):23506–10. <https://doi.org/10.1074/jbc.C100219200> PMID: 11340066
12. Uhrich S, Wu Z, Huang JY, Scott CR. Four mutations in the *S* gene are responsible for the majority of clinical symptoms of CSID. *J Pediatr Gastroenterol Nutr*. 2012; 55(suppl 2):S34–5. <https://doi.org/10.1097/01.mpg.0000421408.65257.b5> PMID: 23103650
13. Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr*. 2012; 55(suppl 2):S7–13. <https://doi.org/10.1097/01.mpg.0000421401.57633.9>
14. Chumpitazi BP, Robayo-Torres CC, Opekun AR, Nichols Bl Jr, Naim HY. Congenital sucrase-isomaltase deficiency: summary of an evaluation in one family. *J Pediatr Gastroenterol Nutr*. 2012; 55(suppl 2):S36. <https://doi.org/10.1097/01.mpg.0000421409.65257.fc> PMID: 23103651
15. Henstrom M, Diekmann L, Bonfiglio F, Hadizadeh F, Kuech EM, von Kockritz-Blickwede M, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut*. 2018; 67(2):263–70. <https://doi.org/10.1136/gutjnl-2016-312456> PMID: 27872184
16. Garcia-Etxebarria K, Zheng T, Bonfiglio F, Bujanda L, Dlugosz A, Lindberg G, et al. Increased prevalence of rare sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. *Clin Gastroenterol Hepatol*. 2018; 16(10):1673–76. <https://doi.org/10.1016/j.cgh.2018.01.047> PMID: 29408290
17. Nouhravesh N, Ahlberg G, Ghose J, Andreasen C, Svendsen JH, Haunsø S, et al. Analyses of more than 60,000 exomes questions the role of numerous genes previously associated with dilated cardiomyopathy. *Mol Genet Genomic Med*. 2016; 4(6):617–23. <https://doi.org/10.1002/mgg3.245> PMID: 27896284
18. Tarailo-Graovac M, Zhu JYA, Matthews A, Wasserman WW. Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders. *Genet Med*. 2017; 19(12):1300–8. <https://doi.org/10.1038/gim.2017.50> PMID: 28471432
19. Chumpitazi BP, Lane MM, Czyzewski DI, Weidler EM, Swank PR, Shulman RJ. Creation and initial evaluation of a Stool Form Scale for children. *J Pediatr*. 2010; 157(4):594–7. <https://doi.org/10.1016/j.jpeds.2010.04.040> PMID: 20826285
20. Opekun AR, Balesh AM, Shelby HT. Use of the biphasic ^{13}C -sucrose/glucose breath test to assess sucrose maldigestion in adults with functional bowel disorders. *Biomed Res Int*. 2016; 2016:7952891. <https://doi.org/10.1155/2016/7952891> PMID: 27579322
21. Treem WR, Ahsan N, Sullivan B, Rossi T, Holmes R, Fitzgerald J, et al. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. *Gastroenterology*. 1993; 105(4):1061–8. [https://doi.org/10.1016/0016-5085\(93\)90950-h](https://doi.org/10.1016/0016-5085(93)90950-h) PMID: 8405850

22. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. *J Pediatr Gastroenterol Nutr.* 1999; 28(2):137–42. <https://doi.org/10.1097/00005176-199902000-00008> PMID: 9932843
23. McMeans AR. Congenital sucrase-isomaltase deficiency: diet assessment and education guidelines. *J Pediatr Gastroenterol Nutr.* 2012; 55(suppl 2):S37–9. <https://doi.org/10.1097/01.mpg.0000421410.72880.ae> PMID: 23103652
24. Lucke T, Keiser M, Illsinger S, Lentze MJ, Naim HY, Das AM. Congenital and putatively acquired forms of sucrase-isomaltase deficiency in infancy: effects of sacrosidase therapy. *J Pediatr Gastroenterol Nutr.* 2009; 49(4):485–7. <https://doi.org/10.1097/MPG.0b013e3181a4c0df> PMID: 19680155